Side Effects of Drugs Annual

A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
 
 
Elsevier (Verlag)
  • 1. Auflage
  • |
  • erschienen am 31. Oktober 2018
  • |
  • 694 Seiten
 
E-Book | ePUB mit Adobe DRM | Systemvoraussetzungen
E-Book | PDF mit Adobe DRM | Systemvoraussetzungen
978-0-444-64120-5 (ISBN)
 

Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions, Volume 40, first published in 1977, and continually published as a yearly update to the voluminous encyclopedia Meyler's Side Effects of Drugs, presents clinicians and medical investigators with a reliable and critical survey of new data and trends in the area of adverse drug reactions and interactions, with an international team of specialists contributing each year. Topics covered in this release include Central Nervous System Stimulants and Drugs that Suppress Appetite, Antidepressant drugs, Lithium, Drugs of abuse, Hypnotics and sedatives, Antipsychotic Drugs, and much more.

  • Provides a critical yearly survey of the new data and trends regarding the side effects of drugs
  • Authored and reviewed by worldwide pioneers in the clinical and practice sciences
  • Presents an essential clinical on the side effects of drugs for practitioners and healthcare professionals alike
  • Englisch
  • San Diego
  • |
  • Niederlande
  • 15,36 MB
978-0-444-64120-5 (9780444641205)
weitere Ausgaben werden ermittelt
  • Front Cover
  • Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
  • Copyright
  • Contributors
  • Contents
  • Preface
  • Special Reviews in SEDA 40
  • Table of Essays, Annuals 1-39
  • Abbreviations
  • ADRs, ADEs and SEDs: A Bird's Eye View
  • Introduction
  • Analysis of ADEs, ADRs, Side Effects and Toxicity
  • Terminology
  • EIDOS
  • DoTS
  • WHO Classification
  • References on Adverse Drug Reactions
  • Further Reading
  • Pharmacogenomics Considerations
  • Enzymes and Transporters
  • Human Leukocyte Antigens (HLA)
  • Genetic Testing Technology
  • Conclusion
  • References
  • Further Reading
  • Immunological Reactions
  • Type I Reactions (IgE-Mediated Anaphylaxis
  • Immediate Hypersensitivity)
  • Type II Reactions (Cytotoxic Reactions)
  • Type III Reactions (Immune Complex Reactions)
  • Type IV Reactions (Cell-Mediated or Delayed Hypersensitivity Reactions)
  • Other Types of Reactions
  • References
  • Further Reading
  • Analysis of Toxicological Reactions
  • Potentiation Reactions
  • Examples
  • Synergistic Effect
  • Additive Effect
  • Examples
  • Antagonistic Effects
  • Examples
  • Cross References
  • Grades of Adverse Drug Reactions
  • References
  • FDA Pregnancy Categories/Classification of Teratogenicity
  • Category A
  • Category B
  • Category C
  • Category D
  • Category X
  • Category N
  • References
  • Clinicians are suggested to be aware of the information contained in the following literature originating from regulatory agen
  • Conclusion
  • Chapter 1: Central Nervous System Stimulants and Drugs That Suppress Appetite
  • Amphetamine and Amphetamine Derivates [SEDA-35, 1
  • SEDA-36, 1
  • SEDA-37, 1
  • SEDA-38, 1
  • SEDA-39, 1]
  • Organs and Systems
  • Cardiovascular
  • Nervous System
  • Gastrointestinal
  • Death
  • Ecstasy (3,4-Methylenedioxy-N-Methylamphetamine, MDMA)
  • Organs and Systems
  • Pulmonary
  • Liver
  • Nervous System
  • Death
  • Methylphenidate [SEDA-35, 1
  • SEDA-36, 1
  • SEDA-37, 1
  • SEDA-38, 1
  • SEDA-39, 1]
  • Organs and Systems
  • Nervous System
  • Hair
  • Skin
  • Drug-Drug Interaction
  • Methylxanthines
  • Caffeine [SEDA-33, 11
  • SEDA-34, 6
  • SEDA-36, 1
  • SEDA-37, 1
  • SEDA-38, 1
  • SEDA-39, 1]
  • Organs and Systems
  • Nervous System
  • Drug-Drug Interaction
  • Selective Norepinephrine Reuptake Inhibitors Atomoxetine [SEDA-36, 1
  • SEDA-37, 1
  • SEDA-38, 1
  • SEDA-39, 1]
  • Organ and Systems
  • Nervous System
  • Drug-Drug Interactions
  • Vigilance Promoting Drugs
  • Modafinil and Armodafinil [SEDA-36, 1
  • SEDA-37, 1
  • SEDA-38, 1
  • SEDA-39, 1]
  • Organs and Systems
  • Drug-Drug Interactions
  • Pitolisant
  • Drugs That Suppress Appetite [SEDA-36, 1
  • SEDA-37, 1
  • SEDA-38, 1
  • SEDA-39, 1]
  • Phentermine [SEDA-36, 1
  • SEDA-37, 1
  • SEDA-38, 1
  • SEDA-39, 1]
  • Organs and Systems
  • Renal
  • Naltrexone Sustained-Release/Bupropion Sustained-Release [SEDA-37, 1]
  • Organs and Systems
  • Skin
  • Drug-Drug Interactions
  • Parasympathomimetics [SEDA-34, 9
  • SEDA-36, 1
  • SEDA-37, 1
  • SEDA-38, 1]
  • Donepezil [SEDA-36, 1
  • SEDA-37, 1
  • SEDA-38, 1
  • SEDA-39, 1]
  • Organ and Systems
  • Cardiovascular
  • Musculoskeletal
  • Memantine [SEDA-34, 1
  • SEDA-39, 1]
  • Organ and Systems
  • Skin
  • Musculoskeletal
  • Rivastigmine [SEDA-36, 1
  • SEDA-37, 1
  • SEDA-38, 1
  • SEDA-39, 1]
  • Organ and Systems
  • Cardiovascular
  • Musculoskeletal
  • References
  • Chapter 2: Antidepressants
  • General
  • Hematological
  • Upper Gastrointestinal Bleeding
  • Postpartum Hemorrhage
  • Venous Thromboembolism
  • Nervous System
  • Stroke
  • Seizures
  • Jitteriness
  • Emotional Blunting
  • Cardiovascular
  • Vascular Outcomes
  • Acute Myocardial Infarction
  • Endocrine
  • Type 2 Diabetes
  • Pancreatitis
  • Reproductive System (Pregnancy, Development and Infancy)
  • Pregnancy
  • Fetal Malformations
  • Preeclampsia
  • Persistent Pulmonary Hypertension of the Newborn
  • Childhood Psychiatric Disorders
  • Autism
  • ADHD
  • Falls and Fractures
  • Sensory Systems
  • Glaucoma
  • Cataracts
  • Selective Serotonin Reuptake Inhibitors
  • Fluoxetine
  • Interstitial Lung Disease
  • References
  • Chapter 3: Lithium
  • Introduction
  • Organs and Systems
  • Nervous System
  • Cardiovascular
  • Renal
  • Endocrine
  • Dermatologic
  • Pregnancy
  • Drug-Drug Interactions
  • References
  • Chapter 4: Drugs of Abuse
  • Introduction
  • Cannabinoids: Synthetic (Hong)
  • Cardiovascular
  • Respiratory
  • Nervous System
  • Urinary Tract
  • Hepatic
  • Drug-Drug Interactions
  • Cannabinoids: Non-Synthetic (Hong)
  • Cardiovascular
  • Gastrointestinal Tract
  • Mineral Balance
  • Nervous System
  • Drug-Drug Interactions
  • Pregnancy
  • Age
  • Cannabinoids (Ku)
  • Pharmacogenetics
  • Alcohol (BABIN)
  • Cardiovascular
  • HEENT
  • Nervous System
  • Sensory Systems
  • Endocrine
  • Gastrointestinal
  • Skin
  • Musculoskeletal
  • Immunologic
  • Tumorigenicity
  • Age
  • Alcohol (Ku)
  • Pharmacogenetics
  • Benzodiazepines (May)
  • Cardiovascular
  • Oncology
  • CNS
  • Migraine
  • Cognitive Decline
  • Orthopedic
  • Hepatic
  • HEENT
  • Sympathomimetics: Cocaine (May)
  • HEENT
  • Splenic
  • CNS
  • Thrombosis
  • Sympathomimetics: Methamphetamine
  • Pulmonary
  • Endocrine
  • Gastrointestinal
  • Cathinones: Non-Synthetic
  • General Information
  • Khat Overdose
  • Cathinones: Synthetic (Wisner, Hall)
  • General Information
  • Cardiovascular
  • Nervous System/Psychological
  • Death
  • Pharmacogenetics
  • Heroin (Babin)
  • Cardiovascular
  • Respiratory
  • CNS
  • Hematologic
  • Musculoskeletal
  • Heroin (Ku)
  • Pharmacogenetics
  • Prescription/Over-the-Counter Opioids and NPS (FUDIN)
  • Population
  • Law (Regulations)
  • Cardiovascular
  • Endocrine
  • Glucose Metabolism (Methadone)
  • Glucose Metabolism (Buprenorphine)
  • Testosterone
  • Gastrointestinal
  • HEENT
  • Dental
  • Eye
  • Nasal
  • Immunologic
  • Hematologic
  • Nervous System
  • Serotonin Syndrome
  • CNS
  • Cognition
  • Behavioral
  • Mental Illness Associated Overdose
  • Respiratory
  • Renal
  • NPS
  • Fentanyl Analogs
  • MT-45
  • U-47700
  • Opioid Withdrawal
  • Symptoms and AE
  • OUD Withdrawal treatment
  • Abuse-Deterrent
  • Tapentadol
  • Buprenorphine
  • NAS
  • Death
  • Prescription/Over-the-Counter Opioids and Fentanyl Analogs (Ku)
  • Pharmacogenetics
  • Conclusion (Precautionary Note to Clinicians)
  • References
  • Chapter 5: Hypnotics and Sedatives
  • Benzodiazepines and Non-Benzodiazepine Gamma-Aminobutyric Acid (GABA) Agonists [SEDA-37, 5
  • SEDA-38, 4
  • SEDA-39, 5]
  • Review
  • Musculoskeletal System
  • Infection Risk
  • Benzodiazepines [SEDA-37, 5
  • SEDA-38, 4
  • SEDA-39, 5]
  • Special Review
  • Central Nervous System
  • Cardiovascular System
  • Respiratory System
  • Immunologic System
  • Prenatal Exposure
  • Non-Benzodiazepine GABA Agonists [SEDA-37, 5
  • SEDA-38, 4
  • SEDA-39, 5]
  • Central Nervous System
  • Infection Risk
  • Ketamine [SEDA-39, 5]
  • Review
  • Cardiovascular System
  • Endocrine System
  • Infant Exposure
  • Drug-Drug Interaction
  • Melatonin Receptor Agonists
  • l-Tryptophan
  • Melatonin [SEDA-37, 5]
  • Orexin Receptor Antagonists
  • Almorexant
  • Elderly
  • Filorexant
  • Suvorexant
  • Elderly
  • Adolescents
  • Propofol [SEDA-38, 4
  • SEDA-39, 5]
  • Cardiovascular System
  • Infection Risk
  • References
  • Chapter 6: Antipsychotic Drugs
  • General [SEDA-35, 85
  • SEDA-36, 59
  • SEDA-37, 63
  • SEDA-38, 35
  • SEDA-39, 65]
  • Comparative Studies
  • Observational Studies
  • Systematic Reviews
  • Cardiovascular
  • Ear, Nose, Throat
  • Nervous System
  • Sensory Systems
  • Endocrine
  • Metabolism
  • Hematologic
  • Skin
  • Musculoskeletal
  • Urinary Tract
  • Sexual Function
  • Reproductive Function
  • Breasts
  • Immunologic
  • Death
  • Drug-Drug Interactions
  • Diagnosis of Adverse Drug Reactions
  • Individual Drugs
  • Amisulpride [SEDA-36, 59
  • SEDA-37, 67
  • SEDA-38, 38
  • SEDA-39, 69]
  • Controlled Studies
  • Observational Studies
  • Nervous System
  • Psychiatric
  • Urinary Tract
  • Aripiprazole [SEDA-35, 96
  • SEDA-36, 59
  • SEDA-37, 68
  • SEDA-38, 38
  • SEDA-39, 69]
  • Controlled Studies
  • Observational Studies
  • Systematic Reviews
  • Cardiovascular
  • Respiratory
  • Nervous System
  • Psychiatric
  • Electrolyte Balance
  • Hematologic
  • Urinary Tract
  • Skin
  • Sweat Glands
  • Musculoskeletal
  • Susceptibility Factors
  • Drug-Drug Interactions
  • Asenapine [SEDA-37, 69
  • SEDA-38, 39
  • SEDA-39, 70]
  • Controlled Studies
  • Observational Studies
  • Systematic Reviews
  • Nervous System
  • Brexpiprazole [SEDA-38, 40
  • SEDA-39, 71]
  • Observational Studies
  • Systematic Reviews
  • Cariprazine (SEDA-38, 40
  • SEDA-39, 40)
  • Observational Studies
  • Chlorpromazine [SEDA-35, 85
  • SEDA-36, 59
  • SEDA-37, 69
  • SEDA-38, 40
  • SEDA-39, 71]
  • Sensory Systems
  • Clozapine [SEDA-35, 99
  • SEDA-36, 59
  • SEDA-37, 69
  • SEDA-38, 40
  • SEDA-39, 72]
  • Observational Studies
  • Systematic Reviews
  • Cardiovascular
  • Respiratory
  • Nervous System
  • Neuromuscular Function
  • Eyes
  • Endocrine
  • Metabolic
  • Hematologic
  • Gastrointestinal
  • Sexual Function
  • Immunologic
  • Body Temperature
  • Second-Generation Effects
  • Susceptibility Factors
  • Drug-Drug Interactions
  • Fluphenazine [SEDA-37, 71
  • SEDA-39, 74]
  • Musculoskeletal
  • Haloperidol [SEDA-35, 107
  • SEDA-36, 59
  • SEDA-37, 72
  • SEDA-38, 42
  • SEDA-39, 74]
  • Systematic Reviews
  • Cardiovascular System
  • Nervous System
  • Overdose
  • Drug-Drug Interactions
  • Iloperidone [SEDA-35, 109
  • SEDA-36, 59
  • SEDA-37, 72
  • SEDA-38, 43
  • SEDA-39, 75]
  • Observational Studies
  • Levosulpiride [SEDA-37, 72
  • SEDA-38, 43
  • SEDA-39, 75]
  • Nervous System
  • Lurasidone [SEDA-37, 72
  • SEDA-38, 43
  • SEDA-39, 75]
  • Controlled Studies
  • Hematologic
  • Nervous System
  • Psychiatric
  • Olanzapine [SEDA-32, 99
  • SEDA-33, 104
  • SEDA-34, 66
  • SEDA-35, 108
  • SEDA-36, 59
  • SEDA-37, 73
  • SEDA-38, 43
  • SEDA-39, 75]
  • Observational Studies
  • Cardiovascular
  • Nervous System
  • Psychiatric
  • Endocrine
  • Electrolytes
  • Hematologic
  • Gastrointestinal
  • Mouth and Teeth
  • Endocrine
  • Skin
  • Sexual
  • Immunologic
  • Body Temperature
  • Second-Generation Effect
  • Drug Administration
  • Overdose
  • Paliperidone [SED-33, 108
  • SEDA-35, 85
  • SEDA-36, 59
  • SEDA-37, 74
  • SEDA-38, 44
  • SEDA-39, 77]
  • Observational Studies
  • Cardiovascular
  • Nervous System
  • Endocrine
  • Electrolytes
  • Immunologic
  • Second Generation
  • Quetiapine [SEDA-36, 59
  • SEDA-37, 74
  • SEDA-38, 45
  • SEDA-39, 78]
  • Controlled Studies
  • Cardiovascular
  • Psychiatric
  • Metabolic
  • Hematologic
  • Gastrointestinal
  • Liver
  • Musculoskeletal
  • Risperidone [SEDA-36, 59
  • SEDA-37, 75
  • SEDA-38, 46
  • SEDA-39, 80]
  • Observational Studies
  • Cardiovascular
  • Nervous System
  • Sensory Systems
  • Endocrine
  • Metabolism
  • Hematologic
  • Skin
  • Musculoskeletal
  • Sexual Function
  • Body Temperature
  • Susceptibility Factors
  • Ziprasidone [SEDA-36, 59
  • SEDA-37, 75
  • SEDA-38, 47
  • SEDA-39, 81]
  • Controlled Studies
  • Zuclopenthixol
  • Systematic Reviews
  • References
  • Chapter 7: Antiepileptics
  • GABA Receptor Agonists [1R, 2R]
  • Clobazam
  • Clonazepam
  • Diazepam
  • Lorazepam
  • Phenobarbital
  • Primidone
  • GABA Reuptake Inhibitors [1R, 2R]
  • Tiagabine
  • GABA Transaminase Inhibitors [1R, 2R]
  • Vigabatrin
  • Drugs With Potential GABA Mechanism of Action [1R, 2R]
  • Gabapentin
  • Pregabalin
  • Valproic Acid/Divalproex Sodium
  • Neurological
  • Dermatological
  • Endocrine/Reproductive
  • Toxicological
  • Miscellaneous
  • Special Review
  • Sodium Channel Blockers [1R, 2R]
  • Carbamazepine
  • Dermatological
  • Rheumatological
  • Hematological
  • Eslicarbazepine acetate
  • Lacosamide
  • Lamotrigine
  • Hematological
  • Neurological
  • Toxicological
  • Oxcarbazepine
  • Phenytoin
  • Zonisamide
  • Glutamate Blockers [1R, 2R]
  • Felbamate
  • Perampanel
  • Topiramate
  • Neuronal Potassium Channel Openers
  • Ezogabine (Retigabine)
  • Other Mechanisms of Action [1R, 2R]
  • Brivaracetam
  • Levetiracetam
  • Ethosuximide
  • Rufinamide
  • References
  • Chapter 8: Opioid Analgesics and Narcotic Antagonists
  • Introduction
  • Opioid Abuse Deterrent Formulations: A Response to the Opioid Epidemic
  • Opioid Receptor Agonists
  • Hydromorphone (SEDA-39, 107-110)
  • Overdose/Intoxication
  • Loperamide
  • Misuse/Abuse/Toxicity
  • Cardiovascular
  • Immunologic
  • Methadone (SEDA-37, 107-114
  • SEDA-38, 71-76
  • SEDA-39, 107-110)
  • Thermoregulation
  • Respiratory
  • Endocrine/Metabolic
  • Morphine (SEDA-37, 107-114
  • SEDA-38, 71-76
  • SEDA-39, 107-110)
  • Pharmacogenetics
  • Oxycodone
  • Immunologic
  • Neurological
  • Neuromuscular Function
  • Tapentadol (SEDA-38, 71-76
  • SEDA-39, 107-110)
  • Cardiovascular
  • Tramadol
  • Neuropsychological
  • Cardiovascular
  • Mixed Agonist-Antagonist/Partial Opioid Agonist
  • Buprenorphine (SEDA-37, 107-114
  • SEDA-39, 107-110)
  • Fetotoxicity
  • Vascular
  • References
  • Chapter 9: Anti-Inflammatory and Antipyretic Analgesics and Drugs Used in Gout
  • AnIline Derivatives [SEDA-37, 115
  • SEDA-38, 77]
  • Paracetamol (Acetaminophen) [SEDA-37, 115
  • SEDA-38, 77]
  • Cardiac
  • Dermatologic
  • Hematologic
  • Sensory
  • Overdose
  • Image 3
  • Acetaminophen Use During Pregnancy
  • Arylalkanoic Acid Derivatives [SEDA-37, 116
  • SEDA-38, 79]
  • Diclofenac [SEDA-37, 116
  • SEDA-38, 79]
  • Gastrointestinal
  • Immunology
  • Skeletal Muscle
  • Ibuprofen [SEDA-37, 117
  • SEDA-38, 79]
  • Gastrointestinal
  • Overdose
  • Pulmonary
  • Ketorolac [SEDA-37, 118]
  • Pulmonary
  • Image 3
  • Precision Trial
  • Indoleacetic Acids [SEDA-37, 121
  • SEDA-38, 79]
  • Indomethacin [SEDA-37, 121
  • SEDA-38, 79]
  • Pharmacogenetics
  • Oxicams [SEDA-37, 121
  • SEDA-38, 79]
  • Meloxicam
  • Cardiovascular
  • Image 1Comparative Studies of NSAIDs
  • Cardiovascular
  • Gastrointestinal
  • Immunologic
  • Salicylates [SEDA-37, 122
  • SEDA-38, 80]
  • Acetylsalicylic Acid (Aspirin) [SEDA-37, 122
  • SEDA-38, 80]
  • Drug Resistance
  • Overdose
  • Drugs Used in the Treatment of Gout [SEDA-37, 123
  • SEDA-38, 80]
  • Allopurinol [SEDA-37, 123
  • SEDA-38, 80]
  • Immunologic
  • Colchicine [SEDA-37, 124
  • SEDA-38, 82]
  • Musculoskeletal
  • Overdose
  • Febuxostat [SEDA-37, 125
  • SEDA-38, 82]
  • Hematologic
  • Musculoskeletal
  • Lesinurad [SEDA-38, 83]
  • Urinary Tract
  • Rasburicase [SEDA-37, 123
  • SEDA-38, 80]
  • Hematologic [SEDA-38, 83]
  • References
  • Chapter 10: General Anesthetics and Therapeutic Gases
  • Inhaled Anesthetics
  • Metabolism
  • Nervous System
  • Tumorigenicity
  • Desflurane
  • Gastrointestinal
  • Respiratory
  • Isoflurane
  • Urinary Tract
  • Nervous System
  • Gastrointestinal
  • Nitrous Oxide
  • Nervous System
  • Gastrointestinal
  • Sevoflurane
  • Respiratory
  • Dexmedetomidine
  • Gastrointestinal
  • Dexmedetomidine and Its Use as an Adjunct in Regional Anesthesia
  • Nervous System
  • Nervous System
  • Case 1
  • Case 2
  • Respiratory
  • Cardiovascular
  • Nervous System
  • Respiratory
  • Nervous System
  • Cardiovascular
  • Intravenous Anesthetic Agents
  • Drug Dosing Regimens
  • Nervous System
  • Case 1
  • Case 2
  • Case 3
  • Endocrine
  • Etomidate
  • Nervous System
  • Ketamine
  • Respiratory
  • Case report
  • Sensory Systems
  • Nervous System
  • Case report
  • Drug Tolerance
  • Neuromuscular
  • Case report
  • Genotoxicity
  • Cardiovascular
  • Case report
  • Urinary Tract
  • Propofol
  • Immunologic
  • Sensory Systems
  • Nervous System
  • Case report
  • Drug Dosing Regimens
  • Respiratory
  • Methohexital
  • Drug Dosing Regimens
  • References
  • Chapter 11: Local Anesthetics
  • Introduction
  • Chloroprocaine
  • Dibucaine
  • Lidocaine
  • Mepivacaine
  • Efficacy and Safety of Lidocaine in the Older Population
  • Lignocaine
  • Bupivacaine Liposome Formulation
  • Anesthetics Liposome Delivery System
  • Lipid Emulsion Rescue Therapy
  • Protective Effect of Intravenous Lipid Emulsion on Mitochondria and Myocytes
  • N-Acetyl Cysteine and Chondrocytes
  • l-Carnitine and Bupivacaine Cardiotoxicity
  • Intravenous Lipid Emulsion Therapy in Term Pregnancy
  • Dermatology Allergy
  • References
  • Chapter 12: Neuromuscular Blocking Agents and Skeletal Muscle Relaxants
  • Depolarizing Neuromuscular Blocking Agents
  • General
  • Succinylcholine (Suxamethonium) (SEDA-36, 173
  • SEDA-37, 155
  • SEDA-38, 105)
  • General
  • Neuromuscular
  • Sensory System: Eye
  • Susceptibility Factors
  • Genetic Factors
  • Drug Administration: Drug Dosage Regimen
  • Interactions: Drug-Drug Interaction
  • Non-Depolarizing Neuromuscular Blocking Agents
  • General
  • Organs and Systems
  • Respiratory
  • Long-Term Effects: Death
  • Cisatracurium
  • Susceptibility Factors
  • Genetic Factors
  • CW002
  • Drug Administration: Drug Dosage Regimen
  • Mivacurium
  • Susceptibility Factors
  • Age
  • Rocuronium (SEDA-38, 107)
  • Organs and Systems
  • Musculoskeletal
  • Drug Administration: Drug Dosage Regimen
  • Interactions: Drug-Drug Interaction
  • Vecuronium
  • Interactions: Drug-Drug Interaction
  • Neuromuscular Blockers: Reversal Agents
  • Sugammadex (SEDA-37, 157
  • SEDA-38, 108)
  • Image 1
  • Specialty Review
  • Organs and Systems
  • Endocrine
  • Immunologic
  • Susceptibility Factors: Physiological Factors
  • Skeletal Muscle Relaxants
  • General
  • Baclofen (SEDA-36, 173
  • SEDA-37, 158
  • SEDA-38, 110)
  • Organs and Systems
  • Nervous System
  • Psychological
  • Long-Term Effects
  • Drug Dependence
  • Drug Administration: Drug Formulation
  • Drug Administration: Drug Dosage Regimen
  • Drug Administration: Drug Administration Route
  • Botulinum Toxin (SEDA-36, 174
  • SEDA-37, 159
  • SEDA-38, 110)
  • Organs and Systems
  • Neuromuscular
  • Sensory System
  • Gastrointestinal
  • Skin
  • Organs and Systems
  • Urinary Tract
  • Carisoprodol (SEDA-37, 160
  • SEDA-38, 111)
  • Long-Term Effects
  • Drug Withdrawal
  • Cyclobenzaprine (SEDA-36, 175
  • SEDA-38, 111)
  • Organs and Systems
  • Sexual Function
  • References
  • Chapter 13: Drugs That Affect Autonomic Functions or the Extrapyramidal System
  • Drugs That Stimulate Both Alpha- and β2-Adrenoeptors [SEDA-33, 313
  • SEDA-34, 233
  • SEDA-35, 255
  • SEDA-36, 179
  • SEDA-37, 163 ...
  • Adrenaline (Adrenaline) and Noradrenaline (Noradrenaline) [SEDA-32, 281
  • SEDA-33, 259
  • SEDA-34, 233
  • SEDA-35, 255
  • SEDA-36, ...
  • Ritodrine [SEDA-34, 318
  • SEDA-35, 258
  • SEDA-36, 188
  • SEDA-40, 000]
  • Musculoskeletal
  • Case Report
  • Pseudoephedrine [SEDA-33, 318
  • SEDA-34, 236
  • SEDA-35, 255
  • SEDA-36, 185
  • SEDA-39, 133
  • SEDA-40, 000]
  • Cardiovascular
  • Case Report
  • Drugs That Predominatly Stimulate α1-Adrenoceptors [SEDA-33, 318
  • SEDA-34, 236
  • SEDA-35, 257
  • SEDA-36, 186
  • SEDA-37, 163
  • ...
  • Phenylephrine [SEDA-15, 2808
  • SEDA-32, 283
  • SEDA-33, 318
  • SEDA-34, 236
  • SEDA-38, 117
  • SEDA-39, 134
  • SEDA-40, 000]
  • Clinical Study
  • Randomized Controlled Trial
  • Randomized Controlled Trial
  • Drugs That Stimulate α1-Adrenoceptors [SEDA-33, 265
  • SEDA-34, 285
  • SEDA-35, 257
  • SEDA-36, 187
  • SEDA-37
  • SEDA-38, 117
  • SEDA ...
  • Methoxamine [SEDA-39, 134
  • SEDA-40, 000]
  • Psychiatric
  • Drugs That Stimulate Dopamine Receptors [SEDA-33, 266
  • SEDA-34, 283
  • SEDA-35, 262
  • SEDA-36, 190
  • SEDA-37, 167
  • SEDA-38, 118 ...
  • Safinamide (New Listing)
  • Systemic Reviews
  • Rotigotine [SEDA-35, 264
  • SEDA-37, 167
  • SEDA-38, 119
  • SEDA-39, 136
  • SEDA-39, 136
  • SEDA-40, 000].
  • Clinical Study
  • Dopamine Receptor Agonists [SEDA-34, 242
  • SEDA-35, 261
  • SEDA-36, 191
  • SEDA-37, 169
  • SEDA-38, 119
  • SEDA-39, 000]
  • Pramipexole [SEDA-36, 193
  • SEDA-37, 168
  • SEDA-38, 124
  • SEDA-39, 137
  • SEDA-40, 000]
  • Nervous System
  • Case Report
  • Psychiatric
  • Case Report
  • Levodopa [SEDA-32, 285
  • SEDA-33, 320
  • SEDA-34, 286-8
  • SEDA-35, 259
  • SEDA-36, 192
  • SEDA-37, 169
  • SEDA-38, 122
  • SEDA-39, 137
  • ...
  • Placebo-Controlled Studies
  • Nervous System
  • Mechanism
  • Miscellaneous Other Drugs That Increase Dopamine Activity
  • Amantadine [SEDA-37, 344
  • SEDA-39, 140
  • SEDA-40, 000]
  • Placebo-Controlled Studies
  • Placebo-Controlled Trials
  • Drugs That Affect the Choliergic System [SEDA-31, 272
  • SEDA-32, 290
  • SEDA-33, 324
  • SEDA-34, 290-1318, SEDA-35, 266
  • SEDA-36 ...
  • Anticholinergic Drugs [SEDA-31, 273
  • SEDA-32, 290
  • SEDA-33, 324
  • SEDA-34, 290-1318
  • SEDA-35, 266
  • SEDA-36, 199
  • SEDA-37, 17 ...
  • Gastrointestinal
  • Case Report
  • Imidafenacin [SEDA-35, 266
  • SEDA-38, 125
  • SEDA-40, 000]
  • Clinical Study
  • Tiotropium [SEDA-35, 319
  • SEDA-36, 247
  • SEDA-37, 199
  • SEDA-38, 124
  • SEDA-39, 141
  • SEDA-40, 000]
  • Placebo-Controlled Trials
  • Clinical Study
  • Clinical Study
  • Solifenacin [SEDA-35, 266
  • SEDA-38, 125
  • SEDA-39, 000]
  • Systematic Review
  • Placebo-Controlled Trials
  • Clinical Study
  • References
  • Chapter 14: Dermatological Agents
  • Anti-infective Agents
  • Benzoyl Peroxide
  • Clindamycin
  • Biologics
  • Adalimumab
  • Adalimumab, Etanercept and Ustekinumab
  • Adalimumab, Etanercept, Infliximab and Ustekinumab
  • Etanercept
  • Infliximab
  • Ixekizumab
  • Secukinumab
  • Ustekinumab
  • Corticosteroids
  • Betamethasone
  • Clobetasol
  • Phosphodiesterase-4 Enzyme Inhibitors
  • Apremilast
  • Crisaborole
  • Retinoic Acid Derivatives
  • Isotretinoin
  • Tazarotene vs Adapalene
  • Tretinoin
  • References
  • Chapter 15: Antihistamines (H1 Receptor Antagonists)
  • Bilastine (SEDA-37, 185
  • SEDA-38, 143
  • SEDA-39, 157)
  • Nervous System
  • Safety for Long-Term Use
  • Nervous System
  • Diphenhydramine (SEDA-36, 233
  • SEDA-37, 185
  • SEDA-38, 143)
  • Cardiovascular
  • Nervous System, Gastrointestinal
  • Psychological/Psychiatric
  • Neuromuscular Function
  • Skin
  • Fexofenadine (SEDA-39, 158)
  • Skin, Immunologic
  • Ketotifen (SEDA-38, 143
  • SEDA-39, 158)
  • Immunologic
  • Levocetirizine (SEDA-36, 233
  • SEDA-37, 185
  • SEDA-38, 143
  • SEDA-39, 158)
  • Nervous System
  • Promethazine (SEDA-36, 233
  • SEDA-37, 185
  • SEDA-38, 143)
  • Drug Abuse
  • References
  • Chapter 16: Drugs That Act on the Respiratory Tract
  • Inhaled Glucocorticoids [SEDA-36, 241
  • SEDA-37, 195
  • SEDA-38, 153
  • SEDA-39, 161]
  • Glaucoma Risk
  • Low Trauma Fractures
  • Case Reports
  • Leukotriene Modifiers [SEDA-36, 245
  • SEDA-37, 197
  • SEDA-38, 153
  • SEDA-39, 166]
  • Montelukast
  • Pranlukast
  • Phosphodiesterase Inhibotors [SEDA-35, 321
  • SEDA-36, 252
  • SEDA-37, 201
  • SEDA-38, 152
  • SEDA-39, 167]
  • Roflumilast
  • ß2-Adrenoceptor Agonists [SEDA-36, 245
  • SEDA-37, 197
  • SEDA-38, 153
  • SEDA-39, 163]
  • Salbutamol
  • Formoterol
  • Olodaterol
  • Vilanterol
  • Theophylline
  • Anticholinergic Drugs [SEDA-36, 245
  • SEDA-37, 197
  • SEDA-38, 153
  • SEDA-39, 165]
  • Glycopyrronium
  • Tiotropium
  • Umeclidinium
  • Anti-Fibrotic Therapies
  • Pirfenidone
  • Pirfenidone Case Studies
  • Nintedanib
  • Immunological Therapies [SEDA-38, SEDA-39]
  • Omalizumab
  • Interleukin-5 Monoclocal Antibodied [SEDA-39, 168]
  • Mepolizumab
  • References
  • Chapter 17: Positive Inotropic Drugs and Drugs Used in Dysrhythmias
  • Cardiac Glycosides [SEDA-36, 257
  • SEDA-37, 205
  • SEDA-15, 173]
  • Digoxin
  • Cardiovascular
  • Electrolyte Balance
  • Mouth
  • Drug-Drug Interaction
  • Antidsyrhythmic Drugs
  • Adenosine [SEDA-17, 330
  • SEDA-17, 379
  • SEDA-15, 36
  • SEDA-30, 212]
  • Cardiovascular
  • Amiodarone [SEDA-36, 259
  • SEDA-37, 208
  • SEDA-15, 173]
  • Skin and Endocrine
  • Liver
  • Sensory Systems (Eyes)
  • Pancreas
  • Respiratory
  • Electrolyte Balance
  • Diltiazem [SEDA-18, 144
  • SEDA-11, 154]
  • Nervous System
  • Skin
  • Dofetilide [SEDA-37, 209
  • SEDA-38, 170
  • SEDA-15, 175]
  • Cardiovascular
  • Dronedarone [SEDA-17, 205
  • SEDA-35, 338
  • SEDA-36, 262]
  • Hematologic
  • Flecainide [SEDA-35, 339
  • SEDA-36, 262
  • SEDA-15, 175]
  • Drug Overdose
  • Hemodynamic Instability
  • Cardiovascular
  • Mexiletine [SEDA-34, 298
  • SEDA-35, 341
  • SEDA-17, 211]
  • Skin
  • Quinidine [SEDA-17, 390
  • SEDA-15, 2997
  • SEDA-30, 219]
  • Skin
  • Hematologic
  • Sotalol [SEDA-15, 3170
  • SEDA-17, 211]
  • Respiratory
  • Cardiovascular
  • Inotropes
  • Norepinephrine
  • Skin
  • Levosimendan [SEDA-34, 291
  • SEDA-17, 258]
  • References
  • Chapter 18: Beta Adrenergic Antagonists and Antianginal Drugs
  • Beta-Adrenoreceptor Antagonists [SEDA-35, 351
  • SEDA-36, 267
  • SEDA-37, 215
  • SEDA-38, 173]
  • Drug Class
  • Cardiovascular
  • Increased Risk for Cardiovascular Events and Severe Hypoglycemia With Beta Adrenergic Antagonist Use in Diabetes Patients
  • Metoprolol
  • Psychiatric
  • Worsening of Depressive and High Burnout Symptoms Associated With Metoprolol in Heart Failure Patients With Mental Health D ...
  • Drug-Drug Interaction
  • Acute Myocardial Infarction From Coronary Vasospasm Precipitated by Pseudoephedrine and Metoprolol
  • Nebivolol
  • Dermatological
  • Lichenoid Type Cutaneous Hyperpigmentation Induced by Nebivolol
  • Carvedilol
  • Worsening Heart Failure
  • Worsening Heart Failure NYHA Class I With Use of Carvedilol for Heart Rate Control in Atrial Fibrillation
  • Labetalol-Nicardipine
  • Infection Risk
  • Impact on Occurrence of In-Hospital Infection of Labetalol vs Nicardipine in Hypertensive Patients With Intracranial Hemorrhage
  • Propranolol
  • Body Temperature
  • Temperatre Instability Associated With Propanolol in Infantile Hemagioma
  • Drug Overdose
  • Cardiac Arrest Following Overdose of Amitriptyline and Propanolol and Pregabalin
  • Drug-Drug Interaction
  • Ventricular Extrasystoles Associated With Concomitant Sofosbuvir
  • Timolol
  • Psychiatric
  • Hallucinations Associated With Ocular Timolol Use in Glaucoma
  • Calcium Channel Blockers [SEDA-35, 354
  • SEDA-36, 270
  • SEDA-37, 219
  • SEDA-38, 175]
  • Amlodipine
  • Fluid Balance
  • Pediatric Cases of Amlodipine-Induce Edema
  • Mouth and Teeth
  • Patient Cases of Amlodipine-Induced Gingival Hyperplasia
  • Infection Risk
  • Nasopharyngitis Assoicated With Amlodipine Use
  • Overdose
  • Patient Case of Suicide Attempt With Amlodipine
  • Drug Interactions
  • Rhabdomyolysis With Concomitant Amlodipine, Atorvastatin and Ticagrelor
  • New Insight on Enantiomer Attributed to Amlodipine Side Effects
  • Verapamil
  • Drug Interactions
  • Verapamil-Rivaroxaban Pharmacokinetic Modelling and Bleed Risk Potential
  • Central Nervous System Effects of Verapamil With an Efflux Transporter Inhibitor
  • Diltiazem
  • Overdose
  • Cases of Hypotension and Shock From Diltiazem Overdose
  • Nifedipine
  • Overdose
  • Toddler Fatality From Nifedipine Overdose
  • Drug Interactions
  • Nifedipine-Candesartan Combination Pharmacokinetics and Tolerability Investigated
  • Felodipine
  • Drug Interaction
  • Felodipine-Enalapril Pharmacokinetics and Side Effects Investigated
  • Barnidipine
  • Fluid Balance
  • Rates of Edema With Barnidipine
  • Image 1
  • Nifedipine Use in Pregnancy
  • Adjuvants to Nifedipine for Preeclampsia
  • Mouth and Teeth
  • Potassium Channel Activators [SEDA-35, 353
  • SEDA-36, 270
  • SEDA-37, 219
  • SEDA-38, 176]
  • Nicorandil
  • Skin
  • Ulceration of Penile Glans Associated With Nicorandil Use
  • Nervous System
  • Acute Intractable Headache and Oculomotor Nerve Palsy Associated With Nicorandil
  • Nitrates [SEDA-34, 305
  • SEDA-35, 354
  • SEDA-38, 176]
  • Nitroglycerin
  • Cardiovascular
  • Hypotension Following Prehospital Administration of Nitroglycerin in Patients With Chest Pain and Tachycardia
  • Pregnancy
  • Nitroglycerin Does Not Protect Against Extension, and Sublingual Nitroglycerin Associated With Adverse Neonatal Outcomes
  • Late Sodium Channel (INA) Inhibitors [SEDA-38, 176]
  • Ranolazine
  • Cardiovascular
  • Gastrointestinal
  • References
  • Chapter 19: Drugs Acting on the Cerebral and Peripheral Circulations
  • Drugs Used in the Treatment of Migraines
  • Triptans [SEDA-36, 277
  • SEDA-37, 223
  • SEDA-39, 180]
  • Drugs Used in the Treatment of Erectile Dysfunction
  • Phosphodiesterase Type 5 Inhibitors [SEDA-37, 275-276
  • SEDA-39, 180-181]
  • Sildenafil
  • New Formulation
  • Sexual Dysfunction
  • Cerebral Venous Sinus Thrombosis
  • Miscellaneous
  • Tadalafil
  • Genitourinary Disorders
  • Cerebral Venous Sinus Thrombosis
  • Miscellaneous
  • Udenfail
  • Drugs Used in the Treatment of Pulmonary Arterial Hypertension
  • Phosphodiesterase Type 5 Inhibitors [SEDA-37, 275-276
  • SEDA-39, 180-181]
  • Sildenafil
  • Endothelin Receptor Antagonist
  • Bosentan
  • Macitentan
  • Peripheral Vasodilators
  • Phosphodiesterase-3 Inhibitors
  • Milrinone
  • Peripheral Vasoconstrictors
  • Image 1
  • Angiotensin II
  • Epinephrine
  • Midodrine
  • Pseudoephedrine
  • Miscellaneous Medications Associated With Cerebrovascular Sequelae
  • Acute Ischemic Stroke
  • Synthetic Cannabinoids (Spice, K2, etc.)
  • Thalidomide
  • Reversible Cerebral Vasoconstriction Syndrome (RCVS) and Posterior Reversible Encephalopathy Syndrome (PRES)
  • Gemcitabine and Cisplatin
  • Tacrolimus
  • References
  • Chapter 20: Antihypertensive Drugs
  • Angiotensin-Converting Enzyme Inhibitors [SEDA 39: 183-187]
  • Enalapril
  • Mouth and Teeth
  • Ramipril
  • Mouth and Teeth
  • Angiotensin Receptor Blockers/Angiotensin II Receptor Antagonists
  • Telmisartan
  • Cardiovascular
  • Gastrointestinal
  • Angiotensin II Receptor Blocker
  • Angiotensin Receptor Neprilysin Inhibitor
  • Valsartan/Sacubitril
  • General Information
  • Drug-Drug Interaction
  • Nervous System
  • Beta Blockers
  • Atenolol
  • Mouth and Teeth
  • Carvedilol
  • Cardiovascular
  • Propranolol
  • Drug-Drug Interaction
  • Nervous System
  • Drug Overdose
  • Calcium Channel Blockers
  • Amlodipine
  • General Information
  • Nicardipine
  • Respiratory/Hematologic
  • Drugs That Act on the Sympathetic Nervous System
  • Urapidil
  • Mouth and Teeth
  • Fixed-Dose Antihypertensive Combination Therapies
  • Indapamide/Perindopril
  • General Information
  • Triple-Combination Therapy
  • General Information
  • References
  • Chapter 21: Diuretics
  • Carbonic Anhydrase Inhibitors [SEDA-37, 237
  • SEDA-38, 197
  • SEDA-39, 191]
  • Acetazolamide
  • Pulmonary Edema
  • Brain Infarction
  • Choroidal Effusion
  • Safety of Acetazolamide for Preoperative Intraocular Pressure Reduction
  • Loop Diuretics [SEDA-37, 237
  • SEDA-38, 185
  • SEDA-39, 189]
  • Respiratory-Related Morbidity and Mortality in Chronic Obstructive Pulmonary Disease
  • Vertebral Fractures
  • Furosemide
  • Risk of Fractures and Fall in the Elderly
  • Increased Oxidative Stress in Acute Kidney Injury
  • Tolerance to Diuretic Therapy
  • Acute Pancreatitis
  • Severe Hypokalemia Resulting in Acute Transient Quadriparesis
  • Hyperacute Leucopenia
  • Hyperparathyroidism
  • Torsemide
  • Effect on Warfarin Dosage Requirements
  • Thiazide and Thiazide-Like Diuretics [SEDA-37, 239
  • SEDA-38, 199
  • SEDA-39, 192]
  • Hyperuricemia
  • Hyponatremia
  • Osteoporosis and Fracture Risk
  • Cancer Risk
  • Hydrochlorothiazide
  • Photosensitivity
  • Lichen Planus
  • Aldosterone Receptor Antagonists [SEDA-37, 240
  • SEDA-38, 201
  • SEDA-39, 193]
  • Spironolactone
  • Hyperkalemia-Induced Cardiac Arrest
  • Anemia
  • Intracranial Hypertension
  • References
  • Chapter 22: Metal Antagonists and Metals
  • Ammonium Tetrathiomolybdate [SEDA-38, 206
  • SEDA-39, 198]
  • Nervous System
  • Immunologic
  • Cadmium [SEDA-39, 198]
  • Endocrine
  • Kidney
  • Cobalt
  • Cardiovascular
  • Deferasirox [SEDA-35, 420
  • SEDA-36, 323
  • SEDA-37, 259
  • SEDA-38, 206
  • SEDA-39, 199]
  • Gastrointestinal
  • Liver
  • Urinary Tract
  • Skin
  • Immunologic
  • Susceptibility Factor: Age
  • Deferiprone [SEDA-35, 422
  • SEDA-36, 327
  • SEDA-37, 264
  • SEDA-38, 207]
  • Gastrointestinal
  • Deferoxamine [SEDA-35, 423
  • SEDA-37, 265
  • SEDA-38, 207]
  • Ear-Nose-Throat
  • Liver
  • Dimercaptopropanesulfonic Acid
  • Genetic Factors
  • Edetic Acid (EDTA) [SEDA-35, 372
  • SEDA-37, 265]
  • Kidney
  • Hydroxyurea [SEDA-36, 330
  • SEDA-37, 266
  • SEDA-38, 208
  • SEDA-39, 200]
  • Respiratory
  • Nervous System
  • Hematologic
  • Skin
  • Hair Nails
  • Reproductive System
  • Immunologic
  • Long-Term Effects: Tumorigenicity
  • Susceptibility Factors: Age
  • d-Penicillamine [SEDA-35, 424
  • SEDA-36, 330
  • SEDA-37, 267
  • SEDA-38, 208
  • SEDA-39, 203]
  • Dermal
  • Polystyrene Sulphonates and Related Drugs [SEDA-35, 427
  • SEDA-36, 333
  • SEDA-37, 268
  • SEDA-38, 209
  • SEDA-39, 203]
  • Endocrine
  • Gastrointestinal
  • Hematologic
  • Physiological Factors
  • Tiopronin [SED-15, 3430
  • SEDA-35, 373
  • SEDA-37, 268]
  • Titanium
  • Hair Nails
  • Vanadium
  • Skin
  • Death
  • Zinc
  • References
  • Chapter 23: Antiseptic Drugs and Disinfectants
  • All Commonly Used Antiseptics and Disinfectants [SEDA-37, 273]
  • Respiratory
  • Immunologic
  • Fertility
  • Aldehydes [SED-15, 1439, 1513
  • SEDA-31, 409
  • SEDA-32, 437
  • SEDA-33, 479
  • SEDA-34, 377
  • SEDA-36, 339
  • SEDA-37, 273
  • SEDA-38, ...
  • Formaldehyde
  • Tumorigenicity
  • Immunologic
  • Nervous System
  • Fetotoxicity
  • Glutaraldehyde (Glutaral)
  • Cardiovascular
  • Immunologic
  • Guanidines
  • Chlorhexidine [SED-15, 714
  • SEDA-31, 410
  • SEDA-32, 439
  • SEDA-33, 480
  • SEDA-34, 378
  • SEDA-36, 340
  • SEDA-37, 273
  • SEDA-38, 21 ...
  • Drug Formulations
  • Skin
  • Immunologic
  • Sensory Systems
  • Mouth and Teeth
  • Polyhexamethylene Guanidine [SEDA-36, 341
  • SEDA-37, 273
  • SEDA-38, 213
  • SEDA-39, 211]
  • Respiratory
  • Benzalkonium Compounds [SED-15, 421
  • SEDA-32, 440
  • SEDA-33, 481
  • SEDA-34, 379
  • SEDA-36, 341
  • SEDA-37, 273
  • SEDA-38, 213
  • SE ...
  • Sensory Systems
  • Respiratory
  • Triclosan [SEDA-34, 379
  • SEDA-36, 342
  • SEDA-37, 276
  • SEDA-39, 212]
  • Nervous System
  • Immunologic
  • Metabolism
  • Halogens
  • Sodium Hypochlorite [SED-15, 3157
  • SEDA-28, 262
  • SEDA-34, 380
  • SEDA-36, 342
  • SEDA-37, 273
  • SEDA-38, 214
  • SEDA-39, 213]
  • Teeth
  • Iodophors [SED-15, 1896
  • SEDA-31, 411
  • SEDA-32, 440
  • SEDA-33, 485
  • SEDA-34, 380
  • SEDA-36, 342
  • SEDA-37, 273
  • SEDA-38, 215
  • ...
  • Iodine
  • Endocrine
  • Polyvinylpyrrolidone (Povidone) and Povidone-Iodine
  • Nervous System
  • Skin
  • References
  • Chapter 24: Beta-Lactams and Tetracyclines
  • Carbapenems
  • Ertapenem
  • Organs and Systems
  • Nervous System
  • Hematologic
  • Meropenem
  • Organs and Systems
  • Hematologic
  • Electrolyte Balance
  • Interactions
  • Drug-Drug Interactions
  • Penicillins
  • Amoxicillin
  • Organs and Systems
  • Respiratory
  • Ampicillin
  • Organs and Systems
  • Nervous System
  • Nafcillin
  • Interactions
  • Drug-Drug Interaction
  • Penicillin
  • Cardiovascular
  • Piperacillin
  • Organs and Systems
  • Cardiovascular
  • Urinary Tract
  • Skin
  • Susceptibility Factors
  • Age
  • Cephalosporins
  • Cefazolin
  • Organs and Systems
  • Urinary Tract
  • Immunologic
  • Cefepime
  • Organs and Systems
  • Nervous System
  • Ceftaroline
  • Organs and Systems
  • Hematologic
  • Ceftazidime-Avibactam
  • General Adverse Drug Reactions
  • Ceftolozane-Tazobactam
  • General Adverse Drug Reactions
  • Ceftriaxone
  • Organs and Systems
  • Cardiovascular
  • Nervous System
  • Hematologic
  • Cefuroxime
  • Organs and Systems
  • Nervous System
  • Sensory Systems
  • Immunologic
  • Tetracyclines and Glycyclines
  • Doxycycline
  • Organs and Systems
  • Skin
  • Susceptibility Factors
  • Age
  • Minocycline
  • Organs and System
  • Nervous System
  • Skin
  • Tigecycline
  • Organs and Systems
  • Hematologic
  • General Adverse Drug Reactions
  • References
  • Chapter 25: Miscellaneous Antibacterial Drugs
  • Aminoglycosides [SEDA-35, 463
  • SEDA-36, 363
  • SEDA-37, 293
  • SEDA-38, 229
  • SEDA-39, 229]
  • Pediatric
  • Psychiatric
  • Pulmonary
  • Sensory Systems
  • Amikacin [SEDA-35, 463
  • SEDA-36, 363
  • SEDA-37, 294
  • SEDA-38, 229
  • SEDA-39, 229]
  • Sensory Systems
  • Paromomycin
  • Skin
  • Gentamicin [SEDA-35, 463
  • SEDA-36, 364
  • SEDA-37, 294
  • SEDA-38, 229
  • SEDA-39, 230]
  • Gastrointestinal
  • Sensory systems
  • Urinary Tract
  • Tobramycin [SEDA-35, 464
  • SEDA-36, 365
  • SEDA-37, 295
  • SEDA-38, 229
  • SEDA-39, 230]
  • Ear, Nose and Throat
  • Pulmonary
  • Fluoroquinolones [SEDA-36, 464
  • SEDA-36, 365
  • SEDA-37, 295
  • SEDA-38, 231
  • SEDA-39, 231]
  • Cardiovascular
  • Gastrointestinal
  • Musculoskeletal
  • Reproductive System
  • Sensory System
  • Levofloxacin [SEDA-35, 465
  • SEDA-36, 366
  • SEDA-37, 296
  • SEDA-38, 232
  • SEDA-39, 232]
  • Nervous System
  • Pediatric
  • Moxifloxacin [SEDA-35, 466
  • SEDA-36, 367
  • SEDA-37, 297
  • SEDA-38, 233
  • SEDA-39, 233]
  • Drug-Drug Interactions
  • Glycopeptides [SEDA-35, 466
  • SEDA-36, 368
  • SEDA-37, 298
  • SEDA-38, 234
  • SEDA-39, 234]
  • Dalbavancin [SEDA-37, 297
  • SEDA-38, 234
  • SEDA-39, 234]
  • Drug Studies
  • Teicoplanin [SEDA-35, 467
  • SEDA-36, 368
  • SEDA-37, 298
  • SEDA-38, 235
  • SEDA-39, 234]
  • Drug-Drug Interaction
  • Telavancin [SEDA-35, 467
  • SEDA-36, 369
  • SEDA-37, 298
  • SEDA-38, 234]
  • Urinary Tract
  • Vancomycin [SEDA-35, 467
  • SEDA-36, 369
  • SEDA-37, 298
  • SEDA-38, 235
  • SEDA-39, 235]
  • Drug Dosage Regimens
  • Hematologic
  • Immunologic
  • Monitoring Therapy
  • Pediatric
  • Sensory Systems
  • Urinary Tract
  • Ketolides [SEDA-35, 469
  • SEDA-36, 370
  • SEDA-37, 299
  • SEDA-38, 235
  • SEDA-39, 234]
  • Solithromycin [SEDA-35, 469
  • SEDA-36, 370
  • SEDA-37, 299
  • SEDA-38, 235
  • SEDA-39, 234]
  • Cardiovascular
  • Lincosamides [SEDA-35, 469
  • SEDA-36, 371
  • SEDA-37, 299
  • SEDA-38, 236
  • SEDA-39, 236]
  • Clindamycin [SEDA-38, 235
  • SEDA-39, 236]
  • Gastrointestinal
  • Macrolides [SEDA-35, 469
  • SEDA-36, 371
  • SEDA-37, 299
  • SEDA-38, 236
  • SEDA-39, 236]
  • Reproductive System
  • Sensory Systems
  • Azithromycin [SEDA-35, 469
  • SEDA-36, 371
  • SEDA-37, 299
  • SEDA-38, 236
  • SEDA-39, 236]
  • Cardiovascular
  • Clarithromycin [SEDA-35, 470
  • SEDA-36, 372
  • SEDA-37, 299
  • SEDA-38, 237
  • SEDA-39, 236]
  • Cardiovascular
  • Drug-Drug
  • Psychiatric
  • Skin
  • Oxazolidinones [SEDA-36, 373
  • SEDA-37, 300
  • SEDA-38, 237
  • SEDA-39, 238]
  • Linezolid [SEDA-36, 373
  • SEDA-37, 300
  • SEDA-38, 237
  • SEDA-39, 238]
  • Age-Related
  • Hematologic
  • Metabolic
  • Nervous System
  • Ophthalmic
  • Tedizolid [SEDA-37, 301
  • SEDA-38, 237]
  • Hematologic
  • Polymyxins [SEDA-35, 473
  • SEDA-36, 374
  • SEDA-37, 301
  • SEDA-38, 237
  • SEDA-39, 238]
  • Urinary Tract
  • Colistin [SEDA-35, 473
  • SEDA-36, 374
  • SEDA-37, 301
  • SEDA-38, 237]
  • Nervous System
  • Pediatric
  • Pulmonary
  • Urinary Tract
  • Polymyxin B [SEDA-39, 239]
  • Skin
  • Urinary Tract
  • Streptogramins
  • Trimethoprim and Trimethoprim-Sulfamethoxazole [SEDA-35, 474
  • SEDA-36, 375
  • SEDA-37, 301
  • SEDA-38, 238
  • SEDA-39, 239]
  • Trimethoprim [SEDA-39, 239]
  • Nervous System
  • Trimethoprim-Sulfamethoxazole [SEDA-35, 474
  • SEDA-36, 375
  • SEDA-37, 301
  • SEDA-38, 238
  • SEDA-39, 239]
  • Endocrine
  • Immunologic
  • Nervous System
  • Other Antimicrobial Drugs
  • Daptomycin [SEDA-35, 474
  • SEDA-36, 375
  • SEDA-37, 302
  • SEDA-38, 238
  • SEDA-39, 240]
  • Respiratory
  • References
  • Chapter 26: Antifungal Drugs
  • Antifungal Azoles [SEDA-35, 484
  • SEDA-36, 382
  • SEDA-37, 307
  • SEDA-38, 245]
  • Fluconazole
  • Itraconazole [SEDA-35, 485
  • SEDA-36, 38
  • SEDA-37, 307]
  • Cardiotoxicity
  • Hepatotoxicity
  • Isavuconazole [SEDA-37, 307
  • SEDA-38, 246]
  • Ketoconazole [SEDA-34, 430
  • SEDA-35, 486
  • SEDA-36, 383
  • SEDA-37, 307
  • SEDA-38, 246]
  • Posaconazole [SEDA-33, 553
  • SEDA-34, 430
  • SEDA-35, 486
  • SEDA-36, 383
  • SEDA-37, 307
  • SEDA-38, 247]
  • Voriconazole [SEDA-35, 486
  • SEDA-36, 384
  • SEDA-37, 307
  • SEDA-38, 247]
  • Special Population: Pediatrics
  • Squamous Cell Carcinoma
  • Cardiotoxicity
  • Hepatotoxicity
  • Periostitis
  • Allylamines [SEDA-36, 381
  • SEDA-37, 307
  • SEDA-38, 243]
  • Terbinafine [SEDA-36, 381
  • SEDA-37, 307
  • SEDA-38, 243]
  • Amphotericin [SEDA-35, 483
  • SEDA-36, 382
  • SEDA-37, 307
  • SEDA-38, 244]
  • Pyrimadine Analogues [SEDA-36, 383
  • SEDA-37, 307
  • SEDA-38, 251]
  • Flucytosine
  • Echinocandins [SEDA-33, 556
  • SEDA-34, 434
  • SEDA-35, 489
  • SEDA-36, 388
  • SEDA-37, 307
  • SEDA-38, 251]
  • Micafungin [SEDA-35, 489
  • SEDA-36, 388
  • SEDA-37, 307
  • SEDA-38, 251]
  • Anidulafungin [SEDA-35, 489
  • SEDA-36, 388
  • SEDA-37, 307
  • SEDA-38, 252]
  • Caspofungin [SEDA-33, 556
  • SEDA-34, 434
  • SEDA-35, 490
  • SEDA-36, 389
  • SEDA-37, 307
  • SEDA-38, 252]
  • References
  • Further Reading
  • Chapter 27: Antiprotozoal Drugs
  • Anti-Malarial Drugs
  • Amodiaquine
  • Artemether-Lumefantrine
  • Artesunate-Amodiaquine
  • Dihydroartemisinin-Piperaquine
  • PfSPZ Vaccine
  • Primaquine
  • Artesunate
  • Tafenoquine
  • Leishmaniasis
  • Meglumine Antimoniate
  • Amphotericin B
  • Chagas Disease
  • Benznidazole
  • Other Protozoal Infections
  • Ornidazole
  • Pyrimethamine
  • References
  • Chapter 28: Antiviral Drugs
  • Drugs Active Against Cytomegalovirus
  • Cidofovir [SEDA-35, 503
  • SEDA-36, 401
  • SEDA-37, 329
  • SEDA-38, 261
  • SEDA-39, 269]
  • Letermovir [SEDA-38, 261
  • SEDA-39, 269]
  • Observational Studies
  • Brincidofovir [SEDA-39, 270]
  • Foscarnet [SEDA-35, 504
  • SEDA-36, 403
  • SEDA-37, 329
  • SEDA-38, 262
  • SEDA-39, 270]
  • Observational Study
  • Ganciclovir and Valganciclovir [SEDA-35, 504
  • SEDA-36, 404
  • SEDA-37, 330
  • SEDA-38, 262
  • SEDA-39, 270]
  • Observational Study
  • Combination Study
  • Valaciclovir
  • Drugs Active Against Herpes Viruses [SEDA-35, 507
  • SEDA-36, 407
  • SEDA-37, 332
  • SEDA-38, 263
  • SEDA-39, 271]
  • Acyclovir
  • Famciclovir
  • Neurological
  • Valaciclovir
  • Drugs Active Against Hepatitis Viruses
  • Adefovir [SEDA-35, 507
  • SEDA-36, 409
  • SEDA-37, 333
  • SEDA-38, 264
  • SEDA-39, 272]
  • Direct-Acting Antiviral Protease Inhibitors [DAA-PI] [SEDA-35, 508
  • SEDA-36, 409
  • SEDA-37, 335
  • SEDA-38, 267, 334
  • SEDA-39, ...
  • Entecavir [SEDA-35, 512
  • SEDA-36, 411
  • SEDA-37, 335
  • SEDA-39, 273]
  • Observational Study
  • Ribavirin [SEDA-35, 512
  • SEDA-36, 412
  • SEDA-37, 335
  • SEDA-38, 267
  • SEDA-39, 273]
  • Sofosbuvir [SEDA-37, 335
  • SEDA-38, 268
  • SEDA-39, 273]
  • Observational Study
  • Combination Study
  • Co-Infection
  • Simeprevir [SEDA-38, 269
  • SEDA-39, 274]
  • Combination Study
  • Daclatasvir
  • Observational Study
  • Drugs Active Against Human Immunodeficiency Virus: Combinations
  • Abacavir/Lamivudine/DTG
  • Elvitegravir/Cobicistat/FTC/Tenofovir
  • Observational Studies
  • Drugs Active Against Human Immunodeficiency Virus: Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTI) [SEDA-35, 51 ...
  • Abacavir [SEDA-35, 516
  • SEDA-36, 415
  • SEDA-37, 337
  • SEDA-38, 270
  • SEDA-39, 276]
  • Observational Studies
  • Lamivudine [SEDA-35, 517
  • SEDA-36, 416
  • SEDA-37, 338
  • SEDA-39, 276]
  • Observational Studies
  • Zidovudine [SEDA-35, 517
  • SEDA-36, 417
  • SEDA-37, 338
  • SEDA-38, 272
  • SEDA-39, 276]
  • Drugs Active Against Human Immunodeficiency Virus: Nucleotide Analogue Reverse Transcriptase Inhibitors
  • Tenofovir [SEDA-35, 518
  • SEDA-36, 418
  • SEDA-37, 338
  • SEDA-38, 272
  • SEDA-39, 276]
  • Drugs Active Against Human Immunodeficiency Virus: Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) [SEDA-35, 519
  • S ...
  • Efavirenz [SEDA-35, 519
  • SEDA-36, 420
  • SEDA-37, 339
  • SEDA-38, 273
  • SEDA-39, 277]
  • Observational Studies
  • Pediatric Patients
  • Nevirapine [SEDA-33, 593
  • SEDA-34, 460
  • SEDA-35, 521
  • SEDA-36, 421
  • SEDA-37, 339
  • SEDA-38, 274
  • SEDA-39, 278]
  • Rilpivirine [SEDA-35, 521
  • SEDA-36, 423
  • SEDA-37, 340
  • SEDA-38, 274
  • SEDA-39, 278]
  • Drugs Active Against Human Immunodeficiency Virus: Protease Inhibitors [SEDA-35, 522
  • SEDA-36, 423
  • SEDA-37, 340
  • SEDA-38, ...
  • Atazanavir
  • Observational Study
  • Drugs Active Against Human Immunodeficiency Virus: Inhibitors of HIV Fusion [SEDA-35, 525
  • SEDA-36, 428
  • SEDA-37, 341
  • SEDA ...
  • Enfuvirtide
  • Drugs Active Against Human Immunodeficiency Virus: Integrase Inhibitors [SEDA-35, 525
  • SEDA-36, 428
  • SEDA-37, 342
  • SEDA-38, ...
  • Dolutegravir (DTG)
  • Observational Studies
  • Raltegravir
  • Observational Study
  • Drugs Active Against Human Immunodeficiency Virus: Chemokine Receptor CCR5 Antagonists [SEDA-35, 528
  • SEDA-36, 430
  • SEDA-37 ...
  • Maraviroc
  • Drugs Active Against Influenza Viruses: Neuraminidase Inhibitors [SEDA-35, 528
  • SEDA-36, 431
  • SEDA-37, 344
  • SEDA-38, 277
  • S ...
  • Oseltamivir (Tamiflu)
  • Combination Study
  • Peramivir
  • Other Drugs
  • Imiquimod [SEDA-35, 530
  • SEDA-36, 431
  • SEDA-37, 344
  • SEDA-38, 277
  • SEDA-39, 280]
  • Dermatological Studies
  • Disclaimer
  • References
  • Chapter 29: Drugs in Tuberculosis and Leprosy
  • Aminoglycosides
  • Electrolyte Disturbances
  • Ototoxicity
  • Nephrotoxicity
  • Drug-Drug Interactions
  • Bedaquiline
  • Drug-Drug Interactions
  • Carbapenems
  • Clofazimine
  • Cycloserine
  • Dapsone
  • Hematologic Disorders
  • Hypersensitivity
  • Hepatotoxicity
  • Delamanid
  • Ethambutol
  • Visual Disturbances
  • Fixed Dose Combination Therapy
  • Fluoroquinolones
  • Central Nervous System Disturbances
  • Isoniazid
  • Active TB
  • LTBI
  • Prophylaxis
  • Linezolid
  • Macrolides
  • Pyrazinamide
  • Para-Aminosalicylic Acid
  • Polypeptides (Capreomycin)
  • Rifamycins
  • LTBI
  • Special Populations
  • Terizidone
  • Thioamides
  • Thioacetazone
  • References
  • Chapter 30: Antihelminthic Drugs
  • Albendazole
  • Drug Combination Studies
  • Ivermectin
  • Case Series
  • Observational Study
  • Comparative Studies
  • Combination Studies
  • Nervous System
  • Immunologic
  • Levamisole
  • Nervous System
  • Sensory System
  • Skin
  • Immunologic
  • Mebendazole
  • Placebo-Controlled Trial
  • Oxantel Pamoate
  • Praziquantel
  • Comparative Study
  • Placebo-Controlled Studies
  • Meta-analysis
  • Tribendimidine
  • Comparative Study
  • References
  • Chapter 31: Vaccines
  • Viral Vaccines
  • Dengue Vaccine [SEDA-39, 302-303]
  • General
  • Age
  • Interactions
  • Drug-Drug Interactions
  • Image 1Ebolavirus Vaccine [SEDA-39, 303-304]
  • Epidemiology
  • Transmission and Pathogenesis
  • Clinical Aspects and Presentation
  • Diagnosis, Management, and Outcomes
  • Vaccinations
  • Public Health Implications and Prevention
  • Conclusions
  • General
  • Hepatitis A Virus Vaccine [SED-16, 255-293, 696-706
  • SEDA-38, 308
  • SEDA-39, 304]
  • Drug Administration
  • Drug Dosage Regimen
  • Organs and Systems
  • Immunologic
  • Liver
  • Hepatitis B Virus Vaccine [SED-16, 255-293, 696-706
  • SEDA-37, 384
  • SEDA-38, 307-308
  • SEDA-39, 306-307]
  • General
  • Susceptibility Factors
  • Physiological Factors: Renal Disease
  • Physiological Factors: Hepatic Disease
  • Human Papillomavirus Vaccine (HPV) [SED-16, 255-293
  • SEDA-37, 384
  • SEDA-38, 308-309
  • SEDA-39, 306-307]
  • General
  • Second-Generation Effects
  • Pregnancy
  • Autoimmune Disease
  • Influenza Vaccine [SED-16, 98-106
  • SEDA-37, 385
  • SEDA-38, 309
  • SEDA-39, 307-313]
  • General
  • Susceptibility Factors
  • Age
  • Immunologic
  • Second-Generation Effects
  • Pregnancy
  • Organs and Systems
  • Infection Risk
  • Nervous System
  • Sensory Systems: Eyes
  • Japanese Encephalitis Vaccine [SED-16, 393-396
  • SEDA-37, 393
  • SEDA-38, 319
  • SEDA-39, 313]
  • General
  • Drug Administration
  • Drug Formulations
  • Interactions
  • Drug-Drug Interactions
  • Measles-Mumps-Rubella Vaccine [SED-15, 3555, 3566, 3567, 3569
  • SEDA-35, 575
  • SEDA-36, 473
  • SEDA-37, 391]
  • Organs and Systems
  • Skin
  • Sensory Systems
  • Poliovirus Vaccine [SED-16, 257, 847-853
  • SEDA-38, 320
  • SEDA-39, 315-316]
  • General
  • Drug Dosage Regimens
  • Organ and Systems
  • Infection Risk
  • Skin
  • Immunologic
  • Rotavirus Vaccine [SED-16, 252-256
  • SEDA-36, 473
  • SEDA-37, 391
  • SEDA-39, 316]
  • Organs and Systems
  • Gastrointestinal
  • Immunologic
  • Drug Administration
  • Drug Formulation
  • Varicella/Herpes Zoster Vaccine [SED-16, 260-365
  • SEDA-37, 391
  • SEDA-38, 320
  • SEDA-39, 316-319]
  • General
  • Organs and Systems
  • Skin
  • Sensory Systems
  • Yellow Fever Vaccine [SED-16, 537-540
  • SEDA-37, 392
  • SEDA-38, 321
  • SEDA-39, 318-319]
  • Organs and Systems
  • Skin
  • Nervous System
  • Bacterial Vaccines
  • Anthrax Vaccine [SED-16, 270, 527
  • SEDA-39, 319-320]
  • General
  • Organs and Systems
  • Immunologic
  • Bacillus Calmette-Guérin Vaccines [SED-16, 267, 797-806]
  • General
  • Organs and Systems
  • Respiratory
  • Skin
  • Infection Risk
  • Susceptibility Factors
  • Age and Ethnicity
  • Meningococcal Vaccines [SED-16, 269, 825-829
  • SEDA-37, 393
  • SEDA-38, 322
  • SEDA-39, 322]
  • General
  • Organs and Systems
  • Sensory Systems
  • Immunologic
  • Infection Risk
  • Susceptibility Factors
  • Age
  • Pertussis Vaccines (Including Diptheria-Tetanus-Acellular/Whole-Cell Pertussis Containing Vaccines) [SED-16, 257-258, 216, ...
  • Organs and Systems
  • Skin
  • Second-Generation Effects
  • Pregnancy
  • Pneumococcal Vaccines [SED-16, 836-840
  • SEDA-37, 395
  • SEDA-38, 327
  • SEDA-39, 325-326]
  • Organs and Systems
  • Skin
  • Infection Risk
  • Susceptibility Factors
  • Other: Asplenia
  • Other: Hematology and Oncology
  • Other: Human Immunodeficiency Virus
  • Other: Sickle Cell Anemia
  • Drug Administration
  • Drug Formulations
  • Drug Additives
  • Drug Dosage Regimens
  • Interactions
  • Drug-Drug Interactions
  • Parasitic Vaccines
  • Malaria Vaccines [SED-16, 733-734
  • SEDA-39, 326-327]
  • General
  • Drug Administration
  • Drug Formulations
  • Cross References
  • EBV
  • HBV
  • HPV
  • Influenza Virus
  • MMR
  • Poliovirus
  • Rotavirus
  • VZV
  • BCG
  • References
  • Chapter 32: Blood, Blood Components, Plasma, and Plasma Products
  • Albumin [SEDA-15, 54
  • SEDA-37, 403
  • SEDA-38, 335
  • SEDA-39, 331]
  • Neonates
  • Blood Transfusion [SEDA-15, 529
  • SEDA-37, 404
  • SEDA-38, 336
  • SEDA-39, 331]
  • Erythrocytes
  • Immunologic
  • Infection Risk
  • Granulocytes
  • Platelets
  • Infection Risk
  • Cardiovascular
  • Gastrointestinal
  • Storage
  • Blood Substitutes [SEDA-15, 84
  • SEDA-37, 406
  • SEDA-38, 339
  • SEDA-39, 333]
  • Hemoglobin-Based Oxygen Carriers (HBOC)
  • Plasma and Plasma Products [SEDA-15, 84
  • SEDA-37, 407
  • 38, 340
  • SEDA-39, 333]
  • Alpha1-Antitrypsin
  • C1 Esterase Inhibitor Concentrate
  • Cryoprecipitate
  • Fresh Frozen Plasma
  • Plasma Substitutes [SEDA-37, 408
  • SEDA-38, 341
  • SEDA-39, 334]
  • Dextrans
  • Etherified Starches
  • Hematologic
  • Urinary Tract
  • Gelatin
  • Immunoglobulins [SEDA-15, 1719
  • SEDA-37, 409
  • SEDA-38, 342
  • SEDA-39, 335]
  • Intravenous Immunoglobulin
  • Hematologic
  • Neurologic
  • Renal
  • Ophthalmic
  • Autoimmune
  • Subcutaneous Immunoglobulin
  • Anti-D Immunoglobulin
  • Coagulation Proteins [SEDA-37, 411
  • SEDA-38, 344
  • SEDA-39, 336]
  • Factor I
  • Factor VIIa
  • Factor VIII
  • Factor IX
  • Prothrombin Complex Concentrate
  • von Willebrand Factor (VWF)/Factor VIII Concentrates
  • Erythropoietin and Derivatives [SEDA-37, 413
  • SEDA-38, 346
  • SEDA-39, 338]
  • Thrombopoietin and Receptor Agonists [SEDA-15, 3409
  • SEDA-37, 414, SEDA-38, 347
  • SEDA-39, 339]
  • Transmission of Infectious Agents Through Blood Donation [SEDA-37, 414
  • SEDA-38, 347
  • SEDA-39, 340]
  • Major Review
  • Virus
  • Stem Cells [SEDA-37, 415
  • SEDA-38, 348
  • SEDA-39, 340]
  • Hematopoietic Stem Cells
  • Infusion Reactions
  • Cardiovascular
  • Renal
  • Pediatric
  • Risk Factors
  • Mesenchymal Stem Cells
  • Cardiovascular
  • Oncologic
  • Intravitreal Administration
  • References
  • Further Reading
  • Chapter 33: Vitamins, Amino Acids and Drugs and Formulations Used in Nutrition
  • Vitamin A [SEDA-35, 607
  • SEDA-36, 503
  • SEDA-38, 355
  • SEDA-39, 345]
  • Vitamins of the B Group [SEDA-35, 607
  • SEDA-38, 355
  • SEDA-39, 346]
  • Cobalamins (Vitamin B12)
  • Folic Acid and Folinic Acid (Vitamin B9)
  • Pyridoxine (Vitamin B6)
  • Riboflavin (Vitamin B2)
  • Vitamin C (Ascorbic Acid) [SEDA-34, 531
  • SEDA-35, 609
  • SEDA-38
  • SEDA-39, 349]
  • Vitamin D Analogues [SEDA-34, 532
  • SEDA-35, 609
  • SEDA-38, 355
  • SEDA-39, 349]
  • Vitamin E (Tocopherol) [SEDA-35, 610
  • SEDA-36, 515
  • SEDA-38, 355
  • SEDA-39, 351]
  • Vitamin K Analogues [SEDA-35, 610
  • SEDA-36, 515
  • SEDA-38, 355
  • SEDA-39, 352]
  • Amino Acids [SEDA-35, 610
  • SEDA-36, 515
  • SEDA-38, 355
  • SEDA-39, 352]
  • Arginine
  • Parenteral Nutrition [SEDA-35, 610
  • SEDA-36, 515
  • SEDA-38, 355
  • SEDA-39, 353]
  • Electrolytes and Minerals
  • Contamination and Infections
  • Enteral Nutrition (Non-Oral: Gastric and Jejunal) [SEDA-35, 610
  • SEDA-36, 515
  • SEDA-38, 355
  • SEDA-39, 354]
  • Conflict of Interest
  • References
  • Chapter 34: Drugs That Affect Blood Coagulation, Fibrinolysis and Hemostasis
  • Coumarin Anticoagulants [SEDA-37, 419
  • SEDA-38, 365
  • SEDA-39, 359]
  • Warfarin [SEDA-37, 419
  • SEDA-38, 365
  • SEDA-39, 359]
  • Cardiovascular
  • Pharmacogenomics
  • Bleeding/Thromboembolism
  • Drug Interactions
  • Calciphylaxis
  • Ophthalmic
  • Heparins [SEDA-37, 419
  • SEDA-38, 367
  • SEDA-39, 360]
  • Enoxaparin [SEDA-37, 419
  • SEDA-38, 367
  • SEDA-39, 360]
  • Hematologic
  • Unfractionated Heparin [SEDA-36, 530
  • SEDA-37, 419
  • SEDA-38, 367]
  • Respiratory
  • Drug Dosage Regimens
  • Direct Thrombin Inhibitors [SEDA-37, 422
  • SEDA-38, 368
  • SEDA-39, 361]
  • Argatroban [SEDA-32, 632
  • SEDA-33, 717
  • SEDA-34, 544]
  • Hematologic
  • Bivalirudin [SEDA-35, 619
  • SEDA-38, 368
  • SEDA-39, 361]
  • Hematologic
  • Gender Differences
  • Direct Thrombin Inhibitors [SEDA-37, 422
  • SEDA-38, 368
  • SEDA-39, 361]
  • Dabigatran [SEDA-37, 422
  • SEDA-38, 369
  • SEDA-39, 362]
  • Gastrointestinal
  • Psychiatric
  • Hematologic
  • Musculoskeletal
  • Drug-Drug Interactions
  • Direct Factor XA Inhibitors [SEDA-37, 423
  • SEDA-38, 370
  • SEDA-39, 363]
  • Apixaban [SEDA-34, 546
  • SEDA-38, 370
  • SEDA-39, 363]
  • Hematologic
  • Renal Disease
  • Betrixaban
  • Cardiovascular
  • Special Review
  • Extended Duration Thromboprophylaxis in Acutely Ill Hospitalized Patients
  • Rivaroxaban [SEDA-37, 423
  • SEDA-38, 371
  • SEDA-39, 365]
  • Hematologic
  • Skin
  • Thrombolytic Drugs [SEDA-37, 424
  • SEDA-38, 371
  • SEDA-39, 366]
  • Alteplase [SEDA-37, 424
  • SEDA-38, 371
  • SEDA-39, 366]/Tenecteplase [SEDA-37, 424]
  • Glycoprotein IIb-IIIa Inhibitors [SEDA-37, 426
  • SEDA-38, 372
  • SEDA-39, 367]
  • Abciximab [SEDA-34, 548
  • SEDA-35, 622
  • SEDA-37, 426]
  • Hematologic
  • Eptifibatide [SEDA-37, 426
  • SEDA-38, 372
  • SEDA-39, 367]
  • Hematologic
  • Tirofiban [SEDA-37, 426
  • SEDA-38, 372
  • SEDA-39, 367]
  • Hematologic
  • P2Y12 Receptor Antagonists [SEDA-37, 427
  • SEDA-38, 373
  • SEDA-39, 367]
  • Cangrelor [SEDA-34, 427
  • SEDA-39, 367]
  • Hematologic
  • P2Y12 Receptor Antagonists [SEDA-37, 427
  • SEDA-38, 373
  • SEDA-39, 367]
  • Clopidogrel [SEDA-37, 427
  • SEDA-38, 373
  • SEDA-39, 367]
  • Hematologic
  • Prasugrel [SEDA-37, 429
  • SEDA-38, 374
  • SEDA-39, 368]
  • Hematologic
  • Ticagrelor [SEDA-37, 429
  • SEDA-38, 374
  • SEDA-39, 368]
  • Hematologic
  • Systemic
  • Drug-Drug Interactions
  • Reversal Agents [SEDA-38, 375
  • SEDA-39, 369]
  • Idarucizumab [SEDA-38, 375
  • SEDA-39, 369]
  • References
  • Chapter 35: Gastrointestinal Drugs
  • Acid-Impacting Agents
  • Proton-Pump Inhibitors (PPIs) [SED-16, 1040-1045
  • SEDA-37, 435
  • SEDA-38, 379-385, SEDA-39, 374-379]
  • Cardiovascular
  • Gastrointestinal
  • Urinary Tract
  • Genetic Factors
  • Long-Term Effects
  • Drug-Drug Interaction, Alisertib
  • Drug-Drug Interaction, Clopidogrel
  • Drug-Drug Interaction, Clopidogrel, Prasugrel
  • Drug-Drug Interaction, Clozapine
  • Drug-Drug Interaction, Methotrexate
  • Drug-Drug Interaction, Mycophenolic Acid
  • Drug-Drug Interaction, Neratinib
  • Drug-Drug Interaction, Momelotinib
  • Drug-Drug Interaction, Palbociclib
  • Drug-Drug Interaction, Venlafaxine
  • Anticonstipation and Prokinetic
  • Domperidone [SED-16, 1067-1068
  • SEDA-37, 445
  • SEDA-38, 385
  • SEDA-39, 379-380]
  • Cardiovascular
  • Linaclotide
  • Gastrointestinal
  • Lubiprostone
  • Gastrointestinal, Nausea
  • Metoclopramide [SED-16, 976-980
  • SEDA-37, 446
  • SEDA-38, 385
  • SEDA-39, 380]
  • Nervous System
  • Case Report
  • Methylnaltrexone [SED-16, 953
  • SEDA-39, 380]
  • Cardiology
  • Naloxegol [SEDA-39, 380-381]
  • Naldemedine
  • Plecanatide
  • Polyethylene Glycol
  • Electrolyte Balance
  • Case Report
  • Prucalopride
  • Sodium Picosulfate and Magnesium Citrate [SED-16, 729-732
  • SEDA-39, 381]
  • Case Report
  • Antidiarrheal and Antispasmodic Agents
  • Loperamide [SED-16, 668
  • SEDA-37, 450
  • SEDA-38, 386-387
  • SEDA-39, 382]
  • Cardiology
  • Simethicone
  • Drug-Drug Interaction, Levothyroxine
  • Teduglutide [SEDA-39, 381]
  • Case Report
  • Antiemetic Agents
  • Aprepitant and Fosaprepitant [SED-16, 657
  • SEDA-36, 544
  • SEDA-37, 450
  • SEDA-39, 382]
  • Nervous System
  • Case Report
  • Drug-Drug Interaction, Bosutinib
  • Ondansetron [SED-16, 343-347
  • SEDA-37, 453, SEDA-38, 388
  • SEDA-39, 383]
  • Cardiology
  • Antiinflammatory Agents
  • Aminosalicylates [SED-16, 242-254
  • SEDA-37, 454
  • SEDA-38, 389
  • SEDA-39, 383]
  • Hematologic
  • Case Report, Fetal Anemia
  • Urinary Tract
  • Case Report, Kidney Failure
  • Thiopurines (Azathioprine, 6-Mercaptopurine) [SED-16, 759-781
  • SEDA-37, 455
  • SEDA-38, 389-390
  • SEDA-39, 383-384]
  • Hematologic/Infection Risk
  • Leukopenia and Infection
  • Reproductive System
  • Preconception Use
  • Anticholinergic Agents
  • Scopolamine
  • Drug Withdrawal
  • Case Report
  • Miscellaneous Agents
  • Misoprostol [SED-16, 1063-1068
  • SEDA-38, 391
  • SEDA-39, 384-385]
  • Reproductive System
  • Body Temperature
  • Fever
  • Case Report
  • Octreotide [SEDA-38, 387]
  • Hematologic
  • Case Report
  • Orlistat [SED-16, 392-394
  • SEDA-38, 391
  • SEDA-39, 385]
  • Drug-Drug Interaction, Levothyroxine
  • Biologics
  • Steroids
  • References
  • Further Reading
  • Chapter 36: Drugs That Act on the Immune System: Cytokines and Monoclonal Antibodies
  • Cytokines
  • Avatrombopag
  • Immunologic
  • Colony-Stimulating Factors [SEDA-35, 659
  • SEDA-36, 563
  • SEDA-37, 461]
  • Infectious
  • Interleukins
  • CT-P13
  • Neurologic
  • Infusion Reactions
  • GP2015
  • Infectious
  • Infliximab [SEDA-37, 464
  • SEDA-38, 397
  • SEDA-39, 474]
  • Immunologic
  • Infectious
  • Monoclonal Antibodies
  • Adalimumab [SEDA-37, 462
  • SEDA-38, 397]
  • Neurologic
  • Genetics
  • Atezolizumab [SEDA-39, 473]
  • Endocrine
  • Avelumab
  • Musculoskeletal
  • Bevacizumab [SEDA-37, 465
  • SEDA-38, 398
  • SEDA-39, 465]
  • Ocular
  • Brodalumab
  • Infectious
  • Cetuximab [SEDA-37, 466
  • SEDA-39, 469]
  • Hematologic
  • Denosumab
  • Metabolic
  • Musculoskeletal
  • Dinutuximab [SEDA-38, 399]
  • Neurologic
  • Fenretinide
  • Immunologic
  • Golimumab [SEDA-37, 464]
  • Ocular
  • Ipilimumab [SEDA-38, 400
  • SEDA-39, 472]
  • Cardiac
  • Gastrointestinal
  • Immunologic
  • Immunologic
  • Namilumab
  • Immunologic
  • Natalizumab [SEDA-37, 467]
  • Immunologic
  • Infectious
  • Nivolumab [SEDA-38, 401
  • SEDA-39, 473]
  • Gastrointestinal
  • Immunologic
  • Immunologic
  • Immune Mediated Complications Post Allogeneic Stem Cell Transplant
  • Neurologic
  • Pulmonary
  • Pembrolizumab [SEDA-38, 402
  • SEDA-39, 473]
  • Dermatologic
  • Metabolic
  • Neurologic
  • Ocular
  • Pinatuzumab
  • Hematologic
  • Rituximab [SEDA-37, 467
  • SEDA-38, 403]
  • Hematologic
  • Immunologic
  • Infectious
  • Tocilizumab [SEDA-37, 468]
  • Hepatic
  • Ustekinumab [SEDA-38, 403]
  • Skin
  • Vedolizumab
  • Infectious
  • YS110
  • Dermatologic
  • References
  • Chapter 37: Drugs That Act on the Immune System: Immunosuppressive and Immunostimulatory Drugs
  • Immunosuppressive Drugs
  • Belatacept [SEDA-34, 609
  • SEDA-37, 471
  • SEDA-38, 407
  • SEDA-39, 389]
  • Comparative Studies
  • Immunologic
  • Cyclosporine (Ciclosporin) [SEDA-34, 609
  • SEDA-37, 473
  • SEDA-38, 409
  • SEDA-39, 390]
  • Systematic Reviews
  • Comparative Studies
  • Observational Studies
  • Tumorigenicity
  • Cardiovascular
  • Infection Risk
  • Reproductive System
  • Drug-Drug Interactions
  • Everolimus [SEDA-36, 592
  • SEDA-37, 474
  • SEDA-38, 410
  • SEDA-39, 391]
  • Systematic Review
  • Comparative Studies
  • Observational Studies
  • Cardiovascular
  • Mouth and Teeth
  • Cardiovascular
  • Respiratory
  • Endocrine
  • Fertility
  • Skin
  • Drug-Drug Interactions
  • Fingolimod [SEDA-34, 616
  • SEDA-35, 703
  • SEDA-37, 471
  • SEDA-38, 407
  • SEDA-39, 392]
  • Systematic Review
  • Observational Studies
  • Tumorigenicity
  • Cardiovascular
  • Sensory Systems
  • Drug Withdrawal
  • Glatiramer [SEDA-34, 617
  • SEDA-36, 593
  • SEDA-37, 471
  • SEDA-38, 407
  • SEDA-39, 393]
  • Systematic Review
  • Comparison Studies
  • Observational Studies
  • Immunologic
  • Leflunomide [SED-15, 2015
  • SEDA-36, 594
  • SEDA-37, 471
  • SEDA-38, 407
  • SEDA-39, 393]
  • Systematic Review
  • Comparative Studies
  • Observational Studies
  • Respiratory
  • Hematologic
  • Mouth and Teeth
  • Liver
  • Nails
  • Pregnancy
  • Mycophenolic Acid [SED-15, 2402
  • SEDA-35, 704
  • SEDA-36, 594
  • SEDA-37, 478
  • SEDA-38, 413
  • SEDA-39, 395]
  • Systematic Reviews
  • Comparative Studies
  • Respiratory
  • Fluid Balance
  • Hematologic
  • Gastrointestinal
  • Skin
  • Tumorigenicity
  • Pregnancy
  • Teratogenicity
  • Sirolimus [SEDA-15, 3148
  • SEDA-35, 705
  • SEDA-36, 596
  • SEDA-37, 479
  • SEDA-38, 415
  • SEDA-39, 396]
  • Comparative Studies
  • Cardiovascular
  • Respiratory
  • Metabolism
  • Fluid Balance
  • Skin
  • Drug-Drug Interactions
  • Interference With Diagnostic Tests
  • Tacrolimus [SEDA-15, 3279
  • SEDA-35, 705
  • SEDA-36, 596
  • SEDA-37, 480
  • SEDA-38, 415
  • SEDA-39, 396]
  • Systematic Reviews
  • Comparative Studies
  • Observational Studies
  • Nervous System
  • Sensory Systems
  • Metabolism
  • Hematologic
  • Gastrointestinal
  • Urinary Tract
  • Skin
  • Infection Risk
  • Genetic Factors
  • Drug Overdose
  • Drug-Drug Interactions
  • Temsirolimus [SEDA-36, 592
  • SEDA-37, 471
  • SEDA-38, 407
  • SEDA-39, 389]
  • Systematic Reviews
  • Comparative Studies
  • Observational Studies
  • Respiratory
  • Mouth and Teeth
  • Thiopurines [SEDA-34, 633
  • SEDA-35, 709
  • SEDA-36, 598
  • SEDA-37, 483
  • SEDA-38, 417
  • SEDA-39, 399]
  • Systematic Reviews
  • Comparative Studies
  • Observational Studies
  • Liver
  • Skin
  • Teratogenicity
  • Hematologic
  • Genetic Factors
  • Immunoenhancing Drugs
  • Levamisole [SED-15, 2028
  • SEDA-34, 638
  • SEDA-35, 710
  • SEDA-36, 460
  • SEDA-37, 484
  • SEDA-38, 420
  • SEDA-39, 399]
  • Observational Studies
  • Hematologic
  • Nervous System
  • Cardiovascular
  • Image 1
  • Special Review: Vasculopathy/Vasculitis Associated With Levamisole-Adulterated Cocaine
  • References
  • Chapter 38: Corticotrophins, Corticosteroids, and Prostaglandins
  • Systemic Glucocorticoids
  • Cardiovascular
  • Central Nervous System
  • Endocrine
  • Metabolic
  • Skin
  • Musculoskeletal
  • Other
  • Infection
  • Death
  • Adrenocorticotropin
  • Drug Dosage Regimens
  • Immunologic
  • Alprostadil
  • Epoprostenol
  • Iloprost
  • Cardiovascular
  • Respiratory
  • Misoprostol
  • Prostaglandins and Analogues
  • Cardiovascular
  • Nervous System
  • Selexipag
  • Major Review
  • References
  • Chapter 39: Sex Hormones and Related Compounds, Including Hormonal Contraceptives
  • Estrogens and Derivatives [SEDA-35, 731
  • SEDA-36, 615
  • SEDA-37, 499-500
  • SEDA-38, 433-439
  • SEDA-39, 417-418]
  • Diethylstilbestrol (DES) [SEDA-35, 731
  • SEDA-36, 615
  • SEDA-37, 499-500
  • SEDA-38, 433-439, SEDA-39, 417-418]
  • Hormone Replacement Therapy (HRT) [SEDA-35, 732
  • SEDA-36, 616
  • SEDA-317, 500-501
  • SEDA-38, 434-435]
  • Transgender Population
  • Deep Venous Thromboembolism
  • Prostate Cancer
  • Reactivation of Endometriosis
  • Hepatic Adenomas
  • Glycemic Profile Deterioration
  • Hormonal Contraceptives [SEDA-35, 722
  • SEDA-36, 618, 622-623
  • SEDA-37, 501-504, 506
  • SEDA-38, 436-439]
  • Mental Health
  • Chronic Urticaria
  • Menangiomas
  • Aromatase Inhibitors: Anastrozole [SEDA-35, 735
  • SEDA-36, 619
  • SEDA-37, 504
  • SEDA-39, 423]
  • Autoimmune Hepatitis
  • Gonadotropins, Clomiphene Citrate, and hCG [SEDA-36, 660
  • SEDA-37, 539
  • SEDA-38, 463
  • SEDA-39, 447]
  • Malformations
  • Ovarian Hyperstimulation Syndrome
  • Endometrial Cancer
  • Palinopsia
  • Anabolics, Androgens, and Related Compounds [SEDA-36, 627
  • SEDA-37, 507-508
  • SEDA-38, 439-441
  • SEDA-39, 423]
  • Testosterone [SEDA-36, 631
  • SEDA-37, 509
  • SEDA-38, 439-440
  • SEDA-39, 423-424]
  • Anthropometric and Biochemical Profiles
  • Central Serous Retinopathy
  • Anabolic Steroids [SEDA-35, 738
  • SEDA-36, 627
  • SEDA-37, 507-508
  • SEDA-38, 440-441
  • SEDA-39, 424]
  • Focal Nodular Hyperplasia
  • Renal Infarction
  • Androgen Deprivation Therapy (ADT) and Anti-Androgens [SEDA-35, 740
  • SEDA-36, 628
  • SEDA-37, 508-509]
  • Optic Neuropathy
  • Bilateral Femoral Neck Fractures
  • References
  • Chapter 40: Miscellaneous Hormones
  • Somatotropin (Human Growth Hormone, hGH) [SEDA-36, 661
  • SEDA-37, 542
  • SEDA-38, 463
  • SEDA-39, 448]
  • Oxytocin and Analogues [SEDA-36, 665
  • SEDA-37, 546
  • SEDA-38, 465
  • SEDA-39, 450]
  • Autism Spectrum Disorder
  • Breastfeeding Deficits
  • Atrioventricular Block
  • Somatostatin (Growth Hormone Release-Inhibiting Hormone) and Analogues [SEDA-35, 794
  • SEDA-36, 666
  • SEDA-37, 549
  • SEDA-38, 466]
  • Octreotide
  • Neutropenia
  • Necrotizing Enterocolitis
  • Lanreotide
  • Hepatic Cyst Infection
  • Glycemic Profile Alterations
  • Pasireotide
  • Desmopressin (N-Amino-8-d-Arginine Vasopressin, DDVAP and Analogues) [SEDA-35, 798
  • SEDA-36, 669
  • SEDA-37, 552
  • SEDA-38, 46 ...
  • Arginine Vasopressin
  • Transient Diabetes Insipidus
  • Desmopressin
  • Reset Osmostat
  • Central Pontine Myelinolysis (CPM)
  • Vasopressin Receptor Antagonists [SEDA-35, 797
  • SEDA-36, 668
  • SEDA-37, 552
  • SEDA-38, 466]
  • Tolvaptan
  • Calcimimetics
  • Entelcalcetide
  • Cinacalcet
  • References
  • Chapter 41: Thyroid Hormones, Iodine and Iodides, and Antithyroid Drugs
  • Thyroid Hormones [SEDA-34, 679
  • SEDA-35, 747
  • SEDA-36, 635
  • SEDA-37, 513
  • SEDA-39, 427]
  • Eprotirome
  • Cardiovascular Disorders
  • Cartilage Defect in Dogs
  • Liver Disorders
  • Sex Hormones
  • Levothyroxine
  • Acute Mania
  • Bone Loss
  • Cardiovascular Disorders
  • Drug-Drug Interaction
  • Drug Overdose
  • Multiple Subungual Pyogenic Granulomas
  • Neurodevelopmental Issues
  • Osteoporosis
  • Quality of Life
  • Rheumatoid Arthritis (RA)
  • Small Intestinal Bacterial Overgrowth
  • Vitamin D Deficiency
  • Octreotide
  • Iodine and Iodides [SEDA-35, 752
  • SEDA-36
  • SEDA-37, 514
  • SEDA-39, 429]
  • Dietary Iodine
  • Iodine-Containing Solutions
  • Radioactive Iodine
  • Hoarseness Post Radioiodine Therapy
  • Salivary Gland Dysfunction
  • Weight Gain
  • Antithyroid Drugs [SEDA-35, 754
  • SEDA-36, 638
  • SEDA-37, 518
  • SEDA-39, 430]
  • Common Side Effects
  • Agranulocytosis
  • ANCA-Positive Vasculitis
  • Hepatotoxicity
  • Neonatal Malformation
  • Pancreatitis
  • Respiratory Disorders
  • Miscellaneous Side Effects
  • References
  • Chapter 42: Insulin and Other Hypoglycemic Drugs
  • Alpha-Glucosidase Inhibitors (AGIs) [SEDA-31, 691
  • SEDA-32, 772
  • SEDA-33, 893
  • SEDA-36, 647
  • SEDA-37, 523
  • SEDA-39, 435]
  • Tumorigenicity
  • Acarbose
  • Liver
  • Biguanides [SEDA-34, 687
  • SEDA-36, 647
  • SEDA-37, 523-526
  • SEDA-38, 459-461
  • SEDA-39, 435-436]
  • Metformin
  • Cardiovascular
  • Respiratory
  • Nervous System
  • Sensory Systems
  • Death
  • Tumorigenicity
  • Pregnancy
  • Dipeptidyl Peptidase-4 Inhibitors (DPP4Is) [SEDA-33, 894
  • SEDA-34, 688
  • SEDA-36, 648
  • SEDA-37, 526-528
  • SEDA-38, 454-457
  • S ...
  • Musculoskeletal
  • Saxagliptin
  • Autacoids
  • Sitagliptin
  • Cardiovascular
  • Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists [SEDA-33, 896
  • SEDA-34, 690
  • SEDA-36, 650
  • SEDA-37, 528-530
  • SEDA-38, 457 ...
  • Cardiovascular
  • Insulins [SEDA-34, 685
  • SEDA-36, 645-647
  • SEDA-37, 521-523
  • SEDA-38, 453-454
  • SEDA-39, 439-441]
  • Cardiovascular
  • Musculoskeletal
  • Death
  • Tumorigenicity
  • Meglitinides
  • Cardiovascular
  • Death
  • Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors [SEDA-33, 898
  • SEDA-34, 695
  • SEDA-36, 652
  • SEDA-37, 530-531
  • SEDA-38, 458 ...
  • Canagliflozin
  • Acid-Base Balance
  • Urinary Tract
  • Musculoskeletal
  • Empagliflozin
  • Acid-Base Balance
  • Sulfonylureas (SUs) [SEDA-34, 695
  • SEDA-36, 652
  • SEDA-37, 531-532
  • SEDA-38, 461
  • SEDA-39, 442-443]
  • Cardiovascular
  • Sensory Systems
  • Musculoskeletal
  • Death
  • Tumorigenicity
  • Thiazolidinediones (TZDs) [SEDA-33, 899
  • SEDA-34, 696
  • SEDA-36, 653
  • SEDA-37, 532-534
  • SEDA-39, 443-444]
  • Musculoskeletal
  • Death
  • Tumorigenicity
  • Pioglitazone
  • Cardiovascular
  • References
  • Chapter 43: Use of Antidiabetic, Antihypertensive, and Psychotropic Drugs in Pregnancy
  • Antidiabetic Drugs
  • Allergic Reactions
  • Shoulder Dystocia
  • Neonatal Outcomes
  • Macrosomia
  • Large for Gestational Age (LGA)
  • Hypoglycemia
  • Preterm Birth
  • Birth Weight
  • Other Neonatal Outcomes
  • Preeclampsia
  • Antihypertensive Drugs
  • Any Antihypertensive Drug
  • Coarctation of the Aorta (CoA)
  • Pulmonary Valve Stenosis (PVS)
  • Ebstein Malformation
  • Septal Defects: Perimembranous Ventricular Septal Defects (VSD-PM) and Secundum Atrial Defects (ASD2)
  • Beta-Blockers
  • Centrally-Acting Adrenergic Agents
  • Cardiovascular Effects
  • Hepatitis
  • Preterm Birth
  • Renin-Angiotensin System Blockers
  • Diuretics
  • Calcium Channel Blockers
  • Psychotropic Drugs
  • Antidepressants
  • Bupropion
  • General Malformations and Risks
  • Cardiovascular
  • Mirtazapine
  • General Malformations
  • Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
  • Congenital Malformations
  • Maternal Risks
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Major Malformations
  • Cardiovascular
  • Respiratory
  • Neurocognitive
  • Maternal Risks
  • Dose Adjustment
  • Tricyclic Antidepressants (TCAs)
  • General Malformations and Serious Risks
  • Neurocognitive
  • Maternal Risks
  • Antiepileptics and Mood Stabilizers
  • Carbamazepine
  • Major Malformations
  • Divalproex Sodium
  • Major Malformations
  • Neurocognitive
  • Lamotrigine
  • Lithium
  • General Risks
  • Epstein's Anomaly
  • Antipsychotics
  • Major Malformations
  • Stillbirth or Abortion
  • Neurocognitive
  • Withdrawal
  • Dose Adjustment
  • References
  • Further Reading
  • Chapter 44: Drugs That Affect Lipid Metabolism
  • Bile Acid Sequestrants [SED-15, 1902
  • SEDA-36, 676
  • SEDA-37, 559]
  • Cholestyramine, Colesevelam and Colestipol
  • Cholesterol Absorption Inhibitor [SEDA-39, 457
  • SEDA-35, 810
  • SEDA-36, 677]
  • Ezetimibe
  • Liver
  • Musculoskeletal, Nervous System
  • Nervous System
  • Nicotinic Acid Derivative [SEDA-39, 457
  • SEDA-15, 2512
  • SEDA-36, 679]
  • Niacin
  • Liver
  • Gastrointestinal
  • Fibric Acid Deravitives [SEDA-39, 459
  • SEDA-15, 1358
  • SEDA-35, 812]
  • Fenofibrate
  • Liver
  • Skin
  • Decrease in HDL-Cholesterol
  • HMG-CoA Reductase Inhibitors [SEDA-39, 459
  • SEDA-15, 1632
  • SEDA-35, 812]
  • Musculoskeletal
  • Skin
  • Endocrine
  • Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors [SEDA-39, 462
  • SEDA-38, 474]
  • Alirocumab
  • Evolocumab
  • References
  • Chapter 45: Cytostatic Agents
  • Fluoropyrimidines
  • 5-Fluorouracil
  • Capecitabine
  • Miscellaneous Agents
  • Gemcitabine
  • Doxorubicin
  • Bevacizumab
  • Oxaliplatin
  • Small Molecule Kinase Inhibitors
  • Everolimus
  • Sunitinib
  • Imatinib
  • Dasatinib
  • References
  • Chapter 46: Radiological Contrast Agents and Radiopharmaceuticals
  • Introduction
  • Iodine-Based Contrast Agents [SEDA-33, 963
  • SEDA-34, 749
  • SEDA-35, 863
  • SEDA-36, 695
  • SEDA-37, 583
  • SEDA-38, 493]
  • ICA-Induced Allergic Reactions
  • ICA-Induced CNS Effects
  • ICA-Induced Salivary SE
  • ICA-Induced Endocrine Effects
  • ICA-Induced Nephropathy
  • Strategies to Reduce ICA-Induced Nephropathy
  • Gadolinium-Based Contrast Agents [SEDA-33, 968
  • SEDA-34, 754
  • SEDA-35, 866
  • SEDA-36, 701
  • SEDA-37, 588
  • SEDA-38, 497]
  • Gadolinium Deposition: Brain, Skin, Bone and Liver
  • GBCA-Induced Nephrogenic Systemic Fibrosis
  • In Utero
  • Future Strategies to Prevent GBCA-Induced Side Effects
  • Iron Oxide-Based Contrast Agents [SEDA-33, 970
  • SEDA-34, 757
  • SEDA-37, 590
  • SEDA-38, 499]
  • Echocardiography/Ultrasonographic Contrast Media Side Effects
  • Radiopharmaceuticals [SEDA-15, 3017
  • SEDA-33, 973
  • SEDA-34, 758
  • SEDA-35, 869
  • SEDA-36, 703]
  • Radium (223Ra)
  • Yittrium (90Y)
  • Emerging Product (99mTc-Al2O3 Nanocolloid)
  • References
  • Further Reading
  • Chapter 47: Drugs Used in Ocular Treatment
  • Introduction
  • Medications Used to Treat Glaucoma
  • Prostaglandin (PGF2α) Analogues
  • Latanoprost, Bimatoprost, Travoprost, Tafluprost
  • General
  • Beta-Blockers
  • Timolol
  • Carbonic Anhydrase Inhibitors (CAI)
  • Sympathetic alpha2-Receptor Antagonists
  • Rho Kinase (ROCK) Inhibitors
  • Mydriatics/Cycloplegics
  • Cyclopentolate
  • Atropine
  • Cyclomidril (0.2% Cyclopentolate and 1% Phenylephrine Combination)
  • Phenylephrine
  • Anti-Inflammatory Agents
  • Corticosteroids
  • Prednisolone, Betamethasone, Dexamethasone, Triamcinolone, Fluocinolone Acetonide
  • Anti-Vascular Endothelial Growth Factor (VEGF) Medications
  • Pegaptanib, Bevacizumab, Aflibercept, Ranibizumab, Conbercept
  • General
  • Bevacizumab
  • Ranibizumab
  • Aflibercept
  • Conbercept
  • Antimicrobials
  • General
  • Sulfonamides
  • Aminoglycosides
  • Fluoroquinolones
  • Ciprofloxacin, Gatifloxacin, Moxifloxacin, Levofloxacin, Ofloxacin, Tosufloxacin
  • General
  • Vancomycin
  • Image 1
  • Special Review on Drug Delivery
  • Disclosure
  • References
  • Further Reading
  • Chapter 48: Safety of Complementary and Alternative Medicine (CAM) Treatments and Practices
  • Introduction
  • Methods
  • General Reviews
  • Dietary and Herbal Supplements
  • Adverse Effects: Central Nervous System
  • Adverse Effects: Hematologic Systems
  • Adverse Effects: Cardiac
  • Adverse Effects: Vascular
  • Adverse Effects: Muscle
  • Adverse Effects: Renal
  • Adverse Effects: Hepatic
  • Adverse Effects: Dermatology
  • Adverse Effects: Gastrointestinal
  • Concerns With Herbal Product Contamination
  • Mind-Body Therapies
  • Manipulative and Invasive Therapies
  • Adverse Effects: Homeopathy
  • Conclusions
  • References
  • Further Reading
  • Reviewers
  • Index of Drugs
  • Index of Drug-Drug Interactions
  • Index of Adverse Effects and Adverse Reactions
  • Back Cover

Dateiformat: EPUB
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat EPUB ist sehr gut für Romane und Sachbücher geeignet - also für "fließenden" Text ohne komplexes Layout. Bei E-Readern oder Smartphones passt sich der Zeilen- und Seitenumbruch automatisch den kleinen Displays an. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Bitte beachten Sie bei der Verwendung der Lese-Software Adobe Digital Editions: wir empfehlen Ihnen unbedingt nach Installation der Lese-Software diese mit Ihrer persönlichen Adobe-ID zu autorisieren!

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Dateiformat: PDF
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat PDF zeigt auf jeder Hardware eine Buchseite stets identisch an. Daher ist eine PDF auch für ein komplexes Layout geeignet, wie es bei Lehr- und Fachbüchern verwendet wird (Bilder, Tabellen, Spalten, Fußnoten). Bei kleinen Displays von E-Readern oder Smartphones sind PDF leider eher nervig, weil zu viel Scrollen notwendig ist. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Bitte beachten Sie bei der Verwendung der Lese-Software Adobe Digital Editions: wir empfehlen Ihnen unbedingt nach Installation der Lese-Software diese mit Ihrer persönlichen Adobe-ID zu autorisieren!

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Download (sofort verfügbar)

320,11 €
inkl. 19% MwSt.
Download / Einzel-Lizenz
ePUB mit Adobe DRM
siehe Systemvoraussetzungen
PDF mit Adobe DRM
siehe Systemvoraussetzungen
Hinweis: Die Auswahl des von Ihnen gewünschten Dateiformats und des Kopierschutzes erfolgt erst im System des E-Book Anbieters
E-Book bestellen